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      1.INTRODUCTION 
Microparticles are solid, approximately spherical particles ranging 1-1000 micrometers in size. 
They are made up of polymeric substances, in which the drug is dispersed throughout the microparticles 
matrix. Microparticles are sometimes referred to as micro particles and other synonymous words are micro 
beads, beads and microspheres. 
        Microparticles are small particles that contain an active agent or core material surrounded by a shell 
or coating of polymers. The core can be solid, liquid, or gas. The shell is a continuous, porous or 
nonporous, polymeric layer. Microparticles show different release properties compared to true 
microparticles and an additional feature is that catastrophic drug burst due to rupture of the shell cannot 
occur1. 
Necessity of using Microparticles: 
The conventional drug delivery systems in use, in many cases fail to meet the need of efficient 
drug delivery at the target site/organ and thereby elicit a less efficacious pharmacological response with 
several side effects. However, advances in microparticles have filled this gap to a large extent because of 
following advantages.  
Formulation of Microparticles: 
The preparation of microparticles includes usage of both natural and synthetic polymers. The 
formulation of Microparticles consists of polymers of bio-degradable and non- biodegradable type, as 
carriers materials. 
Types of polymers: 
 Synthetic Polymers 
 Natural polymers 
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SYNTHETIC POLYMERS: 
a) Non-biodegradable polymers: 
Poly methyl methacrylate(PMMA), Acrolein, Glycidyl methacrylate, Epoxypolymers 
 
b) Biodegradable polymers: 
Lactides, Glycolides & their co polymers, Poly alkyl cyanoacrylates, Poly anhydrides 
 
NATURAL POLYMERS: 
Natural polymers obtained from different sources like proteins, carbohydrates and chemically 
modified carbohydrates. 
Proteins: Albumin, Gelatin, Collagen, Pectin, Guar Gum, Xanthun gum. 
Carbohydrates: Agarose, Carrageenan, Chitosan, Starch 
Chemically modified carbohydrates: Poly dextran, Poly starch. 
 
METHODS OF PREPARATION: 
 Emulsion solvent evaporation technique 
 Emulsion cross linking method 
 Coacervation method 
 Spray drying technique 
 Emulsion-solvent diffusion technique 
 Multiple emulsion method 
 Ionic gelation 
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EMULSION SOLVENT EVAPORATION TECHNIQUE: 
In this technique the drug is dissolved in polymer which was previously dissolved in chloroform 
and the resulting solution is added to aqueous phase containing 0.2 % sodium of PVP as emulsifying 
agent. The above mixture was agitated at 500 rpm then the drug and polymer (eudragit) was transformed 
into fine droplet which solidified into rigid microparticles by solvent evaporation and then collected by 
filtration and washed with demineralised water and desiccated at room temperature for 24 hrs. 
Aceclofenac microparticles were prepared by this technique5. 
EMULSION CROSS LINKING METHOD: 
In this method drug was dissolved in aqueous gelation solution which was previously heated for 1 
hr at 40oC. The solution was added drop wise to liquid paraffin while stirring the mixture at 1500 rpm for 
10 min at 35oC, results in w/o emulsion then further stirring is done for 10 min at 15oC.  
Thus the produced microparticles were washed respectively three times with acetone and isopropyl 
alcohol which then air dried and dispersed in 5mL of aqueous glutaraldehyde saturated toluene solution at 
room temperature for 3 hrs for cross linking and then was treated with 100mL of 10mm glycine solution 
containing 0.1%w/v of tween 80 at 37oC for 10 min to block un reacted glutaraldehyde. 
 COACERVATION METHOD: 
Coacervation thermal change, performed by weighed amount of ethyl cellulose was dissolved in 
cyclohexane with vigorous stirring at 80oC by heating. Then the drug was finely pulverized and added 
with vigorous stirring on the above solution and phase separation was done by reducing temperature and 
using ice bath. Then above product was washed twice with cyclohexane and air dried then passed through 
sieve (sieve no. 40) to obtain individual microcapsule.  
Coacervation non solvent addition, developed by weighed amount of ethyl cellulose was dissolved 
in toluene containing propyl-isobutylene in closed beaker with magnetic stirring for 6 hr at 500 rpm and 
the drug is dispersed in it and stirring is continued for 15mins. Then phase separation is done by petroleum 
benzoin with continuous stirring. After that the microcapsules were washed with n-hexane and air dried 
for 2 hr and then in oven at 50oC for 4 hr. 
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SPRAY DRYING TECHNIQUE: 
This was used to prepare polymeric blended microsphere loaded with ketoprofen drug. It involves 
dispersing the core material into liquefied coating material and then spraying the mixture in the 
environment for solidification of coating followed by rapid evaporation of solvent.  
Organic solution of poly (epsilon caprolactone) (PCL) and cellulose acetate butyrate (CAB), in 
different weight ratios and ketoprofen were prepared and sprayed in different experimental condition 
achieving drug loaded microparticles. This is rapid but may loose crystalinity due to fast drying process. 
EMULSION-SOLVENT DIFFUSION TECHNIQUE: 
In order to improve the residence time in colon floating microparticles of ketoprofen were 
prepared using emulsion solvent diffusion technique. The drug polymer mixture was dissolved in a 
mixture of ethanol and dichloromethane (1:1) and then the mixture was added drop wise to sodium lauryl 
sulphate (SLS) solution. The solution was stirred with propeller type agitator at room temperature at 150 
rpm for 1 hr. Thus the formed floating microparticles were washed and dried in a dessicator at room 
temperature. The following microparticles were sieved and collected. 
MULTIPLE EMULSION METHOD: 
Oral controlled release drug delivery of indomethacin was prepared by this technique. In the 
beginning powder drug was dispersed in solution (methyl cellulose) followed by emulsification in ethyl 
cellulose solution in ethyl acetate. The primary emulsion was then re-emulsified in aqueous medium. 
Under optimized condition discrete microparticles were formed during this phase. 
IONIC GELATION: 
Alginate/chitosan particulate system for diclofenac sodium release was prepared using this 
technique. 25% (w/v) of diclofenac sodium was added to 1.2% (w/v) aqueous solution of sodium alginate. 
In order to get the complete solution stirring is continued and after that it was added drop wise to a 
solution containing Ca2+ /Al3+ and chitosan solution in acetic acid. 
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Microparticles which were formed were kept in original solution for 24 hr for internal gellification 
followed by filteration for separation. The complete release was obtained at pH.4-7.2 but the drug did not 
release in acidic pH. 
Advantages of Microparticles:  
  They facilitate accurate delivery of small quantities of potent drugs and reduced concentration of 
the drug at sites other than the target organ or tissue.  
  They provide protection for unstable drugs before and after administration, prior to their 
availability at the site of action.  
  They provide the ability to manipulate the invivo action of the drug, pharmacokinetic profile, 
tissue distribution and cellular interactions of the drug.  
  They enable controlled release of the drug.  
Sometimes, in formulation of microparticles, cross-linking agents are added. The role of cross-linking 
agent is as follows: 
Cross-links: These are bonds that link one polymer chain to another. They can be covalent bonds or ionic 
bonds. Polymer chains can refer to synthetic polymers or natural polymers (such as proteins). When the 
term "cross-linking" is used in the synthetic polymer science field it usually refers to the use of cross-links 
to promote a difference in the polymers physical properties2. 
        When polymer chains are linked together by cross-links, they lose some of their ability to move as 
individual polymer chains. For example, a liquid polymer (where the chains are freely flowing) can be turned into a 
solid or gel by cross-linking the chains together. 
       In polymer chemistry, when a synthetic polymer is said to be cross-linked, it usually means that the entire 
bulk of the polymer has been exposed to the cross-linking method. The resulting modification of mechanical 
properties depends strongly on the cross-link density. Low cross-link densities raise the viscosities of polymer. 
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Intermediate cross-link densities transform gummy polymers into materials that have elastomeric properties 
and potentially high strengths. Very high cross-link densities can cause materials to become very rigid or glassy, 
such as phenol-formaldehyde materials. 
Cross linking Agents: 
       Cross-links can be formed by chemical reactions that are initiated by heat, pressure, change in pH, 
or radiation. For example, mixing of an unpolymerized or partially polymerized resin with specific 
chemicals called cross linking reagents that result in a chemical reaction that forms cross-links.  
Examples:  Imidoester crosslinker dimethyl suberimidate, the NHS-ester cross linker BS3 and formaldehyde, 
glutaraldehyde, vinylsilane etc. 
          Each of these cross linkers induces nucleophilic attack of the amino group of lysine and subsequent 
covalent bonding via the cross linker. The zero-length carbodiimide cross linker EDC  functions by converting 
carboxyl into amine-reactive iso-urea intermediates that bind to lysine residues or other available primary amines. 
SMCC or its water soluble analog, Sulfo-SMCC, are commonly used to prepare antibody-hapten conjugates for 
antibody development. 
Drug Release Kinetics: 
Release of the active constituent is an important consideration in case of Microparticles. The release 
profile from the Microparticles depends on the nature of the polymer used in the preparation as well as on 
the nature of the active drug. The release of drug from both biodegradable as well as non-biodegradable. 
The drugs could be released through the Microparticles by any on the three methods4. 
 Osmotically driven burst mechanism  
 Pore diffusion method.  
 Erosion or degradation of the polymer. 
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Burst mechanism: 
       In this, water diffuses into the core through biodegradable or non-biodegradable coating, creating 
sufficient pressure that ruptures the membrane. The burst mechanism is mainly affected by 3 factors 
namely macromolecule/polymer ratio, particle size of the dispersed macromolecule and the particle size of 
the Microparticles. 
Pore diffusion method: 
  
      It is named so because as penetrating waterfront continue to diffuse towards the core. The dispersed 
protein/drug dissolves creating a water filled pore network through which the active principles diffuses out 
in a controlled manner. 
Polymer erosion: 
Loss of polymer is accompanied by accumulation of the monomer in the release medium. The 
erosion of the polymer begins with the changes in the microstructure of the carrier as water penetrates 
within it leading to the plasticization of the matrix finally leads to the cleavage of the hydrolytic bonds. 
The cleavage of the bond is also facilitated by the presence of the enzyme in the surroundings. The erosion 
of the polymer may either surfacial or it may be bulk leading to the rapid release of water uptake therefore 
determines release profile of the system and depends on type of the polymer, porosity of the polymer 
matrix, protein drug loading3. 
Drug Release from the swellable polymer: 
 
      The entry of water into the polymer matrix followed by swelling and gelation and then diffusion of 
drug through the viscous gel occurs when water-soluble matrices (hydrophilic matrices) are used. 
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Factors affecting the release of the drug from the particulate system in relation to drug, 
microparticles bio-environment: 
Drug 
 Position  in microparticles 
 Molecular weight 
 Physicochemical properties 
 Concentration 
 Interaction with matrix 
 Microparticles 
 Type and amount of the matrix polymer 
 Size and density of the Microparticles 
 Extent of cross linking, denaturation or polymerization. 
 Adjuvants 
Environment 
 pH 
 Polarity 
 Presence of enzyme 
Drug release from the non-biodegradable type of polymers can be understood by considering the 
geometry of the carrier. The geometry of the carrier, whether it is reservoir type where the drug is present 
as core, or matrix type in which drug is dispersed throughout the carrier, governs overall release profile of 
the drug or active ingredients. 
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Reservoir system: 
       Release from the reservoir type system with rate controlling membrane proceeds by first penetration 
of the water through the membrane followed by dissolution of the drug in the penetrating dissolution fluid. 
The  dissolved drug, after partitioning moves through the membrane across the stagnant diffusion layer6. 
      The release is essentially governed by the Fick’s First law of Diffusion as 
J= -D(dc/dx) 
Where, J= flux per unit area 
                 D = Diffusion coefficient 
                dc/dx = concentration gradient. 
Matrix system: 
 Release profile of the drug from the matrix type of the device critically depends on the state of drug 
whether it is dissolved or dispersed in the polymer matrix. In case of the drug dissolved in the polymeric 
matrix, amount of drug and the nature of the polymer10. 
APPLICATION OF MICROPARTICLES 
Microparticles in Vaccine Delivery: 
         The prerequisite of a vaccine is protection against the microorganism of its toxic product. An ideal 
vaccine must fulfill the requirement of efficacy, safety, convenience in application and cost. The aspect of 
safety and minimization of adverse reaction is a complex issue. The aspect of safety and the degree of 
production of antibody responses are closely related to mode of application. The interest in parenteral 
carrier lies since they offer specific advantages including: 
 Improved antigenicity by adjuvant action 
 Modulation of antigen release. 
 Stabilization of antigen. 
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Polymers used for Vaccine Delivery system: 
            Biodegradable polymers belong to a class of choice for the delivery of the vaccine since they do 
not require surgical removal. 
Examples are PLGA polylactic acid, polyglycolic polymers etc. 
Stability of Microparticles in vaccine delivery: 
             Antigen polymer compatibility is a major barrier encountered in the design of a suitable carrier 
because it may lead to the stability problem. The polymer compatibility can be increased by co-
encapsulating buffer salts and stabilizers for proteins which are thought to increase antigen stability by 
modifying the internal pH of Microparticles and accelerating swelling7.  
The use of tri-block copolymers having hydrophilic A block (PLGA or PLA) and hydrophilic B 
block (polyoxyethylene, PEO) also provide stability to the carrier system by providing more gentle and an 
accommodative system. 
Microparticles in Immune system: 
       The interaction of the Microparticles with macrophages depends upon the particle size. 
Microparticles of particle size less than 10micrometers are directly taken up by the antigen presenting 
cells. The microparticles with particle size range greater than 10 micrometers first undergo degradation or 
release of antigens, which are then phagocytosized by antigen presenting cells. The antigen presenting 
cells are responsible for the activation of bad T cells and hence immunological consequences. 
Monoclonal Antibodies mediated Microparticles Targeting Immune: 
            Monoclonal antibodies mediated targeting is a method used to achieve selective targeting to the 
specific sites. Monoclonal antibodies are extremely specific molecules. This extreme specificity of the 
monoclonal antibodies can by utilize to target Microparticles loaded bioactive molecules to selected sites.  
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Mabs can be directly attached to the Microparticles by means of covalent coupling. The free 
aldehyde groups, amino groups, or hydroxyl groups on the surface of the Microparticles can be linked to 
the antibodies.  
Microparticles from different material and prepared using different methods carry different 
functional groups, which help in the coupling of the antibodies.  
The mabs can be attached to the Microparticles by any of the following methods: 
 Non-specific  adsorption  
 Specific adsorption  
 Direct Coupling  
 Coupling via reagents.  
Non-specific adsorption: 
     Mabs can be adsorbed nonspecifically on to the surface of the hydrophobic microparticles by physical 
adsorption, which renders them more hydrophilic. Hydrophilic microparticles are more suitable for the 
cell targeting. Monoclonal antibodies form immune-microparticles on coupling with the microparticles9. 
Specific adsorption: 
      It can be conducted by means of the ligands, which interact directly with intact or modified antibodies. 
Proteins A from Staphylococcus aurueus and avidin biotin are two specific ligands that are used for 
specific adsorption purpose. 
Direct coupling: It is achieved through free functional groups present on the surface of the microparticles. 
The functional Microparticles undergo direct coupling, e.g. polyacrolien microparticles have free 
functional carboxyl groups, which help them to couple with the monoclonal antibodies. 
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Coupling via reagents: 
     Coupling of Microparticles with monoclonal antibodies can also be achieved by means of the reagents 
when Microparticles of choice do not contain functional groups or carry functional groups, which are not 
capable of coupling. Different methods depending on the reagent used include carbodimide method and 
cyanogens bromide method. 
Cancer chemotherapy: 
      Microparticles are used mainly in targeting the tumorous organ. In this, the Microparticles are directly 
administered to the tumorous organ by means of local intra-arterial injection.  
Disadvantages of Microparticles: 
The main disadvantages of Microparticles are as follows:  
 The phagocytosis of colloidal carriers 
 Rapid clearance 
 Passive distribution 
       The change in the biophysical behavior of the particles helps to avoid the difficulties in targeting. 
Different approaches have been utilized to change the surface properties of carriers to protect them against 
phagocytic clearance and to alter their body distribution pattern. 
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Surface Modifiers:  
            They modify the surface properties of carriers in order to achieve the targeting to the discrete 
organs and to avoid rapid clearance from the body. Among the most studied surface modifiers are  
1. Antibodies and their fragments. 
2. Proteins. 
3. Mono, oligo and polysaccharides. 
4. Chelating compounds such as EDTA,  DTPA or Desferroxamine 
5. Synthetic soluble polymers. 
           The surface of the albumin Microparticles can be modified by covalent attachment of polyoxy 
alkyene chain having terminal ether groups. The polyoxyethylene moiety may react with surface amino or 
carboxyl residues by condensation with an appropriate functional group in the presence of the condensing 
agent8. 
Stability and storage: 
        The Microparticles formulations are stored at 25± 2ºC and 60 ± 5% RH for a period of 6 months 
and at 5±  3º C for a period of 12 months, which is the accelerated storage temperature and long-term 
storage temperature, respectively, for products intended to be refrigerated. The decision to refrigerate was 
taken because of the thermo-sensitivity and thermo-liability of the polymers chosen. The stored samples 
are tested for their drug content, particle size distribution and for any physical change. 
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     2.AIM AND OBJECTIVE 
 
       The present work is carried out to formulate and evaluate the Domperidone    
microparticles by ionic gelation technique by using natural polymers. Domperidone is an anti-
dopaminergic drug agent that is used orally, rectally or  intravenously, in general to 
suppress nausea and vomiting. It is a specific blocker of dopamine receptors. It speeds gastrointestinal 
peristalsis and is used as antiemetic 
 The aim of the preparation is to improve the drug-polymer encapsulating capacity of the 
microparticles. So that the microparticles with desired controlled release features are obtained. There are 
many methods to achieve controlled release of drug from the dosage form. Among them, ionic gelation 
method is one. This method, that is, gel forming ability is simple way of obtaining particulate drug 
carriers.  
Studies using natural polymers guar gum, pectin, xanthun gum besides synthetic ones such as 
PLGA, have been carried out. The entrapment efficiency of the microparticles is affected by drug and 
polymer ratio. The domperidone microparticles were prepared by using natural polymers, so as to obtain 
the controlled release of drug from the formulation. 
Natural polymers are known to form reticulated structures, when in contact with calcium ions and 
their characteristics have been used to produce sustained release particulate systems for a variety of drugs. 
Domperidone has been selected as a model drug because it helps to move food faster through food pipe, 
stomach, gut and does not stay in the same place too long providing the required action of emetic. 
 
. 
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3.PLAN OF WORK 
 
The study was proposed to carry out in the following studies: 
 
1. Preformulation Studies 
 
1. Compatibility studies. 
2. Fourier transform infrared spectroscopy (FTIR) 
 
2. Preparation of Standard Calibration Curve for Domperidone 
 
3. Formulation of Microparticles of Domperidone 
 
4. Evaluation of Prepared Microparticles 
 
 Swelling Studies 
 Entrapment Studies 
 In vitro Dissolution Studies. 
 Drug Release  Kinetics 
 Particle size 
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4.LITERATURE SURVEY 
Park H J et al.11  Chitosan microparticles were prepared with tripolyphosphate (TPP) by ionic cross 
linking. The particle sizes of TPP chitosan microparticles were in range from 500 to 710 mm and 
encapsulation efficiencies of drug were more than 90%. The morphologies of TPP-chitosan microparticles 
were examined with scanning electron microscopy. As pH of TPP solution decreased and molecular 
weight (MW) of chitosan increased, microparticles had more spherical shape and smooth surface. Release 
behaviors of felodipine as a model drug were affected by various preparation processes. Chitosan 
microparticles prepared with lower pH or higher concentration of TPP solution resulted in slower 
felodipine release from microparticles. With decreasing MW and concentration of chitosan solution, 
release behavior was increased. The release of drug from TPP-chitosan microparticles decreased when 
cross-linking time increased. These results indicate that TPP-chitosan microparticles may become a 
potential delivery system to control the release of drug. 
Paolo Blasi et al.12  The aim of this work was to develop a novel composite alginate/poly (lactic-co-
glycolic) acid microparticulate system for protein stabilization and delivery using bovine insulin as model 
drug. Alginate particles, prepared by ionic gelation, were embedded into PLGA microparticles using the 
solvent diffusion evaporation technique. Actual loading was determined by micro-BCA protein assay for 
total insulin and by reversed phase-high performance liquid chromatography for soluble insulin. Insulin 
loaded composite microparticles showed reproducible encapsulation efficiency with a higher soluble 
insulin content when compared to conventional microparticles. Bovine insulin in vitro release studies and 
adsorption behavior were investigated in 10mM glycine buffer (pH 2.8) at 37 ◦C. The stability of bovine 
insulin, olubilized in the above mentioned buffer, was studied as well.  
In this case, bovine insulin showed to be instable at the investigated conditions and 55% of insulin was 
lost after 7days. However, composite microparticle release, characterized by a low burst effect, lasted up 
to 4 months. Moreover, no significant peptide adsorption on blank PLGA or blank composite 
microparticles was observed while, a strong interaction between alginate particles and bovine insulin was 
detected. 
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Bataille B et al.13 Experimental factorial designs were built to investigate the effects of five parameters on 
production yields and moisture contents of spray-dried products. These factors concerned both the 
solution feed (drug concentration, colloidal silica concentration and polymer: drug ratio) and the spray 
dryer (inlet temperature and feed rate). Three formulations containing cellulose derivatives and 
acetaminophen were tested. The aim of the study was to optimize the operating conditions to maximize 
production yields while minimizing moisture contents. First screening experiments consisting of fractional 
factorial designs revealed the most significant factors to be inlet temperature, feed rate and their 
interaction for both formulations containing sodium carboxymethyl cellulose and feed rate and colloidal 
silica concentration for the formulation containing microcrystalline cellulose.  
Then, the optimal operating conditions were estimated by response surface methodology. Central 
rotational composite designs showed quadratic models were adequate. New assays were carried out using 
these last conditions to evaluate both the repeatability and reproducibility of the spray-drying technique. 
Yields above 80% and moisture content of _1% were reached. The characterization of microparticles 
revealed the poor flow ability of the spray-dried products due to significant cohesiveness and very small 
size (less than 55 mm). 
Tetsuya Ozeki et al.14  In this study, we used a novel 4-fluid nozzle spray drier to prepare composite 
microparticles of a water-insoluble drug, flurbiprofen (FP), and a water-soluble drug, sodium salicylate 
(SS), for the purpose of improving the water solubility of FP. An ethanol solution of FP and an aqueous 
SS solution were simultaneously introduced through different liquid passages in the 4-fluid nozzle spray 
drier and then spray-dried. Quantitative elemental analysis suggested that the FP/SS ratio in each 
composite microparticle was nearly the same as the formulation ratio. We also found that SS and FP exist 
in a low crystalline state in the composite particles. Release of FP from dissolved composite 
microparticles was markedly improved because of an increase in the effective surface area following rapid 
dissolution of SS. This study shows that it is possible to prepare FP–SS composite microparticles using a 
4-fluid nozzle spray drier in single process and that this can improve the ability of FP to dissolve in water. 
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Yuuki Takashima et al.15  Preparation of nano-sized particles using lyophilization, which is a standard 
drying technique for high-molecular-weight compounds such as bioactive peptides, proteins, plasmid 
DNA and sRNA, often results in particle aggregation. In this study, spray-drying was applied for 
preparation of cationic PLGA nanospheres as gene delivery vectors in order to minimize aggregation and 
loss of gene transfection efficiency. PLGA nanoparticles emulsions were prepared by dropping an 
acetone/methanol mixture (2/1) containing PLGA and a cationic material, such as PEI, DOTMA, DCChol 
or CTAB, into distilled water with constant stirring. The PLGA nanosphere emulsion was dried with 
mannitol by spray-drying, and mannitol microparticles containing PLGA nanosphere were obtained.  
Mean particle diameter of spray dried PLGA particles was 100–250 nm, which was similar to that of the 
nano-emulsion before drying, whereas the lyophilized PLGA particles showed increased particle diameter  
due to particle aggregation. PEI, DOTMA and DC-Chol were useful for maintaining nanoparticles size 
and conferring positive charge to nanosphere. Transfection of pDNA (pCMV-Luc) using these spray-dried 
cationic PLGA nanosphere yielded high luciferase activity in COS-7 cells, particularly with PLGA/PEI 
nanosphere. The present spray-drying technique is able to provide cationic PLGA nanosphere, and may 
improve redispersal and handling properties 
Artusi M et al.16  This study investigated the possibility to use spray drying technique to prepare powders 
formulations containing caffeine intended for nasal delivery. Spray dried powders containing caffeine and 
excipients, as filler and shaper agents, were prepared. Powders were investigated for particle size, 
morphology and delivery properties from Monopowder P® nasal insufflators, assessing the influence of 
each excipient on microparticles characteristics. The results showed that the excipients strongly affected 
microparticle properties. Size, shape and agglomeration tendency are relevant characteristics of spray 
dried nasal powder. 
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Rita Cortesi et al.17  The aim of the present paper was to study production of methacrylate microparticles 
for the delivery (administration) of ascorbic acid via the oral route. Vitamin C is an important antioxidant 
that may be involved in the reduction of the risk of certain types of cancer, such as colorectal cancer. As 
polymers different acrylic compounds were considered, namely Eudragit® RL, L and RS. Spray-drying 
was used as preparation method of vitamin C/Eudragit® microspheres.  
Microspheres were first characterized by size and morphology by scanning electron microscopy, then in 
vitro release kinetics by mean of dialysis method were studied. Although the produced microparticles 
were unable to slow down the release of the drug with respect to the free form of ascorbic acid, these 
microspheres showed a good morphology and size distribution that permit to propose them as candidate 
for the delivery of vitamin C as associated therapy in the treatment of colorectal cancer by oral route. 
Yogesh Pore et al.18  Abstract The aim of the present study was to enhance the physicochemical 
properties of poorly aqueous soluble Carvedilol (CRV) by preparing its microparticles in presence and/or 
in absence of a hydrophilic carrier. The polymeric microparticles of CRV were prepared with 
polyvinylpyrrolidone K30 with or without addition of adsorbents like Aerosil_200 and/or Sylysia_350 by 
using spray drying technique. The dissolution profiles revealed that the drug and polymer ratio and 
colloidal silica both played critical role in solubility enhancement. The spray dried microparticles and drug 
alone were characterized by differential scanning calorimetry (DSC), X-ray powder diffraction, Fourier 
transformation infrared spectroscopy (FTIR), particle size analysis and scanning electron microscopy 
(SEM). DSC analysis showed that CRV transformed from the crystalline state to amorphous state by spray 
drying, confirmed by disappearance of its melting peak. The results of the X-ray analysis were in 
agreement with the thermal analysis data. It did not show characteristic crystalline drug peaks which 
confirmed that the amorphous form of CRV was present in the CRV loaded microparticles. FTIR analysis 
demonstrated hydrogen bonding interaction with an absence of significant chemical interaction between 
CRV and polymer. Spherical microparticles were yielded with smooth surfaces as observed by SEM. All 
in all, this work reveals that spray drying is a suitable technique for preparation of microparticles with 
improved physicochemical properties of CRV. 
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Diego A. Chiappetta et al.19  The aim of this work was to develop indinavir pediatric anti-HIV/AIDS 
formulations enabling convenient dose adjustment, ease of oral administration, and improved organoleptic 
properties by means of the generation of drug-loaded microparticles made of a polymer that is insoluble 
under intake conditions and dissolves fast in the stomach in order to completely release the active agent. 
Indinavir loaded microparticles made of a pH-dependent polymeric excipients soluble at pH<5, Eudragit 
E100, were prepared using a double emulsion solvent diffusion technique and the in vitro release profiles 
characterized. Finally, taste masking properties were evaluated in blind randomized sensory experiments 
by ten healthy human volunteers. The use of a w/o/o emulsion system resulted in indinavir loads around 
90%. Thermal analysis of the microparticles by differential scanning calorimetry revealed that indinavir 
appeared mainly dispersed at the molecular level. Concentrations of residual organic solvents as 
determined by gas chromatography were below the upper limits specified by the European Pharmacopeia 
for pharmaceutical oral formulations. Then, the behavior of drug-containing microparticles  in aqueous 
media at different pH values was assessed. While they selectively dissolved in gastric like medium, in tap 
water (intake conditions), the matrix remained almost unchanged and efficiently prevented drug  
dissolution. Finally, sensoring taste tests performed by volunteers indicated that systems with indinavir 
loads 15% displayed acceptable taste. This work explored the production of indinavir containing 
microparticles based on a common pharmaceutical excipients as a means for the improvement of 
medicines of drugs involved in the treatment of HIV/AIDS. For systems containing about 15% drug, taste 
studies confirmed the acceptability of the formulation. In pediatric regimes, this composition would 
require an acceptable amount of formulation (0.7–1.5 g). 
 
Perumal D et al.20 The emulsion solvent diffusion was employed to prepare modified release 
microspheres of ibuprofen. The technique was optimized for the following processing variables: the 
absence/presence of baffles in the reaction vessel, agitation rate and drying time. Thereafter, the influence 
of various formulation factors on the microencapsulation efficiency, in vitro drug release and micromeritic 
properties was examined. The variables included the methacrylic polymer, Eudragit® RS 100, ibuprofen 
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content and the volume of ethanol used during microencapsulation. The results obtained were then 
interpreted on a triangular phase diagram to map the region of microencapsulation, as well as those 
formulations that yielded suitable modified release ibuprofen microspheres. 
Rajesh Kaza et al.21  The purpose of this study was to prepare controlled release microspheres of 
acyclovir sodium using different polymers like sodium alginate, hydroxyl propyl methyl cellulose and 
sodium carboxy methyl cellulose using calcium chloride as cross linking agent. The microspheres were 
prepared using ionotropic gelation technique. The prepared microspheres were evaluated for particle size 
analysis, drug entrapment efficiency; In vitro drug release and Fourier transform infra red spectroscopy 
(FTIR). The results of study revealed that retention time of acyclovir at its absorption site could be 
increased by formulating it into microspheres using sodium alginate, hydroxyl propyl methyl cellulose and 
sodium carboxy methyl cellulose in different ratios. The acyclovir sodium microspheres prepared from 
sodium alginate and hydroxyl propyl methyl cellulose at the concentrations of 1:2:1.5 weight ratios with 
2% calcium chloride as cross linking agent showed the highest drug release of 98.8 % over a period of 12 
hours. The microspheres prepared were found to be spherical without aggregation and free flowing. The 
percentage yield and drug entrapment in all the formulations were good. The average particle size was 
found to be within the range of 100-200 micrometers.  
All the formulations show excellent flow ability as expressed in terms of angle of repose (< 25°).FTIR 
Spectroscopy reveals that there is no chemical interaction between the drug and excipients. 
Chintagunta Pavanveena et al.22  Trimetazidine hydrochloride‐loaded Gelatin microspheres were 
prepared by the ionic cross‐linking technique using TPP as cross‐linking agent. The process induced the 
formation of microspheres with the incorporation efficiency of 47% to 77%. The effect of Gelatin 
concentration, cross‐linking agents and conditions was evaluated with respect to entrapment efficiency, 
particle size, surface characteristics and in vitro release behaviors. Infrared spectroscopic study confirmed 
the absence of any drug‐polymer interaction. Differential scanning colorimetric analysis revealed that the 
drug was molecularly dispersed in the Gelatin microspheres matrices showing rough surface, which was 
confirmed by scanning electron microscopy study. The mean particle size and entrapment efficiency were 
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found to be varied by changing various formulation parameters. The in vitro release profile could be 
altered significantly by changing various formulation parameters to give a sustained release of drug from 
the microspheres. The kinetic modeling of the release data indicate that trimetazidine hydrochloride 
release from the Gelatin microspheres follow anomalous transport mechanism after an initial lag period 
when the drug release mechanism was found to be fickian diffusion controlled. 
Akanksha Garud et al.23  The purpose of the present study was to prepare, characterize and evaluate the 
colon-targeted microspheres of mesalamine for the treatment and management of ulcerative colitis (UC). 
Microspheres were prepared by the ionic-gelation emulsification method using tripolyphosphate (TPP) as 
cross linking agent.  
The microspheres were coated with Eudragit S-100 by the solvent evaporation technique to prevent drug 
release in the stomach. The prepared microspheres were evaluated for surface morphology, entrapment 
efficiency, drug loading, micromeritic properties and in-vitro drug release. The microspheres formed had 
rough surface as observed in scanning electron microscopy. The entrapment efficiency of microspheres 
ranged from 43.72%-82.27%, drug loading from 20.28%-33.26%. The size of the prepared microspheres 
ranged between 61.22-90.41ȝm which was found to increase with increase in polymer concentration. All 
values are statistically significant as p<0.05. Micromeritic properties showed good flow properties and 
packability of prepared microspheres. The drug release of mesalamine from microspheres was found to 
decrease as the polymer concentration increases. The release profile of mesalamine from eudragit-coated 
chitosan micro-spheres was found to be pH dependent. It was observed that Eudragit S100 coated chitosan 
microspheres gave no release in the simulated gastric fluid, negligible release in the simulated intestinal 
fluid and maximum release in the colonic environment. It was concluded from the study that Eudragit-
coated chitosan microspheres were promising carriers for colon-targeted delivery of Mesalamine. 
Canefe et al.24  Indomethacin-loaded microspheres of ethylcellulose were prepared by the emulsion 
solvent evaporation technique. The aim of this work was to investigate the influence of process variation 
in polymer type via viscosity grades of ethylcellulose N10 and N100, drug to polymer ratio, stirring rate of 
the propeller and surfactant type on the micromeritic properties of microspheres such as                     
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particle size distribution, bulk and tapped density, surface topography, tangent of angle of repose, 
compressibility index, Hausner ratio and flow rates.  
All microspheres presented a narrow particle size distribution and good flow characters according to USP 
28-NF 23 criteria, besides microspheres were more spherical in shape in their manufacture with 
ethylcellulose N100 and higher ratio of both polymers. Thus, in the case of ethylcellulose, the viscosity 
and ratio of the polymer in dispersion medium were found to be the controlling factors of drug release. 
Ethylcellulose N10 and N100 membrane materials indicated difference in release patterns of 
microspheres. Microspheres exhibited lower burst effect with decreased drug release rate, when the drug 
was incorporated with ethylcellulose N100 and higher ratio of each polymer. Therefore, Indomethacin 
release from ethylcellulose microspheres could not be evaluated by any of the kinetic models. 
Basu S K et al.25   The aim of the work was to prepare nitrendipne-loaded Eudragit RL 100 microspheres 
to achieve sustained release nitrendipine. Nitrendipne-loaded Eudragit RL 100 microspheres were 
prepared by an emulsion-solvent evaporation method using ethanol/liquid paraffin system. The resultant 
microspheres were evaluated for average particle size, drug loading, in vitro drug release and release 
kinetics. FTIR spectrometry, scanning electron microscopy, differential scanning calorimetry and x-ray 
powder diffractometry were used to investigate the physical state of the drug in the microspheres. The 
mean particle size of the microspheres was influenced by varying drug: polymer ratio and emulsifier 
concentration while drug loading was dependent on drug: polymer ratio. The results of FTIR 
spectrometry, differential scanning calorimetry and x-ray diffractometry indicated the stable character of 
nitrendipne in drug-loaded microspheres and also revealed absence of drug-polymer interaction. The drug 
release profiles of the microspheres at pH 1.2 showed poor drug release characteristics while at pH 
6.8,drug release was extended over a period of 8 hr release was influenced by polymer concentration and 
particle size. Drug release followed the Higuchi model.  
The nitrendipine-loaded Eudragit RL 100 microspheres prepared under optimized conditions showed a 
good sustained release characteristic and were stable under the conditions studied. 
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Himansu Bhusan Samal et al.26 The present study involves design and characterization of floating 
microspheres with Nateglinide as model drug for prolongation of gastric residence time. Nateglinide 
Floating Microspheres were prepared by w/o/o emulsification solvent diffusion technique using rate 
controlling polymers ethyl cellulose and hydroxy propyl methyl cellulose. The shape and surface 
morphology of prepared microspheres were characterized by optical and scanning electron microscopy 
respectively. FTIR analyses the absences of drug-polymer interaction. In vitro drug release studies were 
performed and drug release kinetics was evaluated using the linear regression method. Effects of polymer 
concentration, solvent composition, particle size, drug entrapment efficiency and drug release were also 
observed. The prepared microspheres exhibited prolonged drug release (more than 12 h) and remained 
buoyant for > 24 hr. The mean particle size increased and the drug release rate decreased at higher 
polymer concentration. In vitro studies demonstrated diffusion- controlled drug release from the 
microspheres. 
 Namdeo k p et al.27  In the present study, spherical microspheres of theophylline (TP) using sodium 
alginate as the hydrophilic carrier were prepared to prolong the release. The shape, surface and size 
characteristics were determined by scanning electron microscopy. The microspheres were found to be 
discreet and spherical in shape and had a smoother surface. The mean diameter of seven alginate 
microspheres formulations were between 7.6 ± 0.52 and 22.35 ±0.31 ȝm. It was observed that mean 
particle size of the microspheres increased with an increase in the concentration of polymer.  
The entrapment efficiency was found to be in the range of 70–93%. Optimized alginate microspheres were 
found to possess good sphericity, size and adequate entrapment efficiency. The in vitro release studies 
were carried out in pH progression media. Results indicated that percent drug release decreased with an 
increased alginate concentration. TP-loaded Alginate microspheres showed extended in vitro drug release 
thus use of microspheres potentially offers sustained release profile along with improved delivery of TP. 
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Nazia Khanam et al.28 The aim of present research work was to formulate and evaluate microspheres of 
Propranolol Hydrochloride to achieve sustained release system using combination of algino-eudragit 
RS100 system by ionic-gelation technique. The prepared microspheres were evaluated for various 
parameters like percentage yield, particle size, flow property, entrapment efficiency, surface study, in-
vitro drug release, X-Ray diffraction analysis, etc. It was found that all formulations showed improved 
flow behavior as compared to pure drug, it was observed that on increasing the polymer concentration of 
formulations the entrapment efficiency and particle size were increased. The surface morphology study by 
SEM indicated that microspheres were spherical with rough outer surface. There was no interaction 
between the drug and the polymers, as studied by FTIR study. In-vitro drug release study showed that on 
microsphere formulation its release was sustained and its release was affected by polymer concentration 
and it followed Higuchi model. Therefore, it can be concluded that Propranolol Hydrochloride loaded 
algino-eudragit RS100 microspheres can be formulated for sustained drug delivery of Propranolol 
Hydrochloride  
 Rohit B Mane et al.29  The aim of this study was to preparation and evaluation of Carvedilol microsphere 
using spray drying technique and to optimize the spray drying parameters to get the optimum formulation. 
The Carvedilol microsphere were prepared by spray drying technique using ethyl cellulose and PEG 6000 
as sustained release polymers. Nine batches were prepared by using ethyl cellulose and PEG 6000 in 
different polymer ratios and prepared microspheres were evaluated for the particle size, percentage drug 
entrapment and percentage drug release. Experimental designs were built to investigate the effects of five 
parameters on production yields and particle size of spray-dried microspheres of Carvedilol. These factors 
concerned aspiration speed, flow rate, drug polymer ratio, temperature difference between inlet 
temperature and outlet temperature. Three formulations containing ethyl cellulose, PEG 6000 and 
Carvedilol were tested. The aim of the study was to optimize the operating conditions to maximize 
production yields while minimizing the particle size. The characterization of microsphere revealed the 
poor flow ability of the spray-dried products due to significant cohesiveness and very small size (less than 
20ȝm). 
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Yupeng Lu et al.30  Hollow hydroxyapatite microspheres were prepared using a simple spray drying 
method. The incorporation of ammonium bicarbonate could produce carbon dioxide and ammonia gas 
bubbles during the spraying, and thus created a hollow inner structure in the resultant microspheres. The 
hollow microspheres prepared using different amounts of ammonium bicarbonate were also characterized. 
These microspheres were composed of nanoparticles with an average crystallite size of 15 nm. A high 
surface area (80 m2/g) and porosity of the microspheres could be achieved when the concentration of 
ammonium bicarbonate was about 5 wt%.  
Fourier transform infrared results showed that CO3 2− was incorporated into the HA microspheres. These 
hollow microspheres have many potential uses such as injectable drug-delivery carriers. 
Muzzarelli A A et al.31  Incubation of the rigid and transparent gel obtained upon pouring a chitosan 
hydrochloride solution into saturated ammonium hydrogen carbonate at 20 8C yielded chitosan carbamate, 
soluble at alkaline pH values, typically 9.6. Addition of water to the gel isolated by centrifugation 
promoted the dissolution of the gel. By spray-drying the alkaline solution thus obtained, microspheres of 
chitosan were obtained. When chitosan carbamate was mixed with alginic acid, polygalacturonic acid, 
carboxymethyl cellulose, carboxymethyl guaran, acacia gum, 6-oxychitin, xanthan, hyaluronic acid, 
pectin, k-carrageenan, and guaran, clear solutions were obtained from which chitosan–polyuronan 
microspheres were easily manufactured by spray-drying. Those made of chitosan–xanthun or chitosan–
guaran were 
unexpectedly found to be soluble in water; similarly, the chitosan–pectin microspheres were almost 
soluble. The microspheres containing hyaluronic acid or k-carrageenan underwent swelling when 
contacted with water; the other ones were insoluble. The microspheres were characterized by FTIR, X-ray 
diffraction spectrometry and scanning electron microscopy. The structural alterations detected were 
mainly due to interactions between the amino groups and the carboxyl groups. 
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Dolores Blanco M et al.32  Ketotifen (KT)-loaded chitosan microspheres (MS) were prepared for 
controlled release of the antihistaminic drug, and their use as delivery systems in the intraperitoneal cavity 
of rats was investigated. Microspheres were prepared by a spray-drying method followed by treating with 
glutaraldehyde solutions in methanol as cross-linker.  
Results showed that very small spherical microspheres (1.0–1.3 lm) with a high load of KT (92 ± 6 lg 
KT/mg) were obtained. KT loading decreased with cross-linking (52 ± 2– 46 ± 7 lg KT/mg). Interactions 
between KT and chitosan avoided total KT release from cross-linked MS. After intraperitoneal (i.p.) 
administration, microsphere aggregations were adhered to muscle subjacent 
to the tegument and to adipose tissue, and there were no evident sings of rejection; KT was detected in 
blood stream (0.37–0.25 lg/mL) at 24 h, which was longer than the i.p. administration of the drug in 
solution (39.4 lg/mL at 2.4 hr). 
 
Hildgen P et al.33  The morphology, the surface structure, and the mean diameter of spray-dried 
biodegradable pegylated microspheres were studied by X-ray photoelectron spectroscopy (XPS) 
technique, scanning electron microscopy (SEM) and photo correlation spectroscopy. PEG 400-distearate 
(PEG-400(C18)2) was incorporated into poly(D,L-lactic acid) (PLA) by spray-drying using different 
concentrations of PLA and polyethylene glycol-distearate (PEG-distearate). The use of these different 
concentrations resulted in systems with different sizes, morphologies and surfaces. Microsphere 
characteristics such as size distribution, morphology, and PEG distribution were investigated and proven 
to be highly dependent on the concentrations of PLA and PEG in the solutions to be spray-dried. Scanning 
electron microscopy showed that the PLA concentration in the polymeric solution rise to microparticles 
rather than microspheres. Red blood cell-like structures were observed for a high PLA concentration. 
Photo correlation spectroscopy proved that the size distribution depended on the initial viscosity of the 
polymeric solution. The more viscous was the solution, the bigger the microspheres (and vice versa). X-
ray photoelectron spectroscopy confirmed the assumption that greater is the amount of PEG-distearate in 
the formulation, the more it is found on the surface. These results have allowed us to predict pegylated 
biodegradable microspheres to be the best microencapsulation process. 
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Pirjo Kortesuo et al.34  The objective of this study was to evaluate sol–gel-derived spray dried silica gel 
microspheres as carrier material for dexmedetomidine HCl and toremifene citrate. The drug was dissolved 
in sol–gel processed silica sol before spray drying with Bu¨ chi laboratory scale equipment. Microspheres 
with a low specific surface area were spherical by shape with a smooth surface without pores on the 
external surface. The particle size distribution was quite narrow. The in vitro release of toremifene citrate 
and dexmedetomidine HCl showed a dose-dependent burst followed by a slower release phase, that was 
proportional to the drug concentration in the concentration range between 3.9 and 15.4 wt.%. The release 
period for toremifene citrate was approximately 10 days and for dexmedetomidine HCl between 7 and 50 
days depending on drug concentration. Spray drying is a promising way to produce spherical silica gel 
particles with a narrow particle size range for controlled delivery of toremifene citrate and 
dexmedetomidine HCl. 
Palmieri F et al.35 Ketoprofen controlled release microspheres were prepared, by emulsion /solvent 
evaporation, at 15 °C, in order to avoid the formation of semisolid particles. An identical procedure was 
carried out at 60 °C to speed up the solvent evaporation and the formed semisolid microspheres were 
directly microencapsulated by complex coacervation and spray-dried in order to recover them as free 
flowing powder. Microspheres and microcapsules were characterized by 
scanning electron microscopy, differential scanning calorimetry, X-ray diffractometry, in vitro dissolution 
studies, and then used for the preparation of tablets. During this step, the compressibility of the prepared 
powders was measured. Microspheres and microcapsules showed compaction abilities by far better than 
those of the corresponding physical mixtures. In fact, it was impossible to obtain tablets by direct 
compressing drug and polymer physical mixtures, but microspheres and microcapsules were easily 
transformed into tablets.  
Finally, in vitro dissolution studies were performed and the release control of the tablets was pointed out. 
Microspheres were able to control Ketoprofen release only after their transformation into tablets. Tablets 
containing eudragit RS were the most effective in slowing down drug release. 
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Paolo Giunchedi et al.36  The work purpose was to study the application of 5-methylpyrrolidinone 
chitosan (MPC) for preparing mucoadhesive microparticles for the nasal administration of drugs. 
Microspheres were produced by the spray-drying technique using MPC; metoclopramide hydrochloride 
(MC) was chosen as model drug. Chitosan microparticles were prepared as a comparison. The 
microparticles obtained were characterized (encapsulation efficiency, morphology, size and drug release 
behavior). In-vitro mucoadhesive tests, swelling tests and ex-vivo studies using sheep nasal mucosa were 
performed. The hydrogel formation from microspheres was studied in different media and at different 
pHs. Microspheres are able to control the in-vitro MC release. MPC microparticles show good in-vitro 
mucoadhesive properties and ex-vivo controlled permeation profiles. The hydrogel formation is dependent 
mainly on the medium used: ionically cross linked hydrogel was hypothesized. These in-vitro and ex-vivo 
preliminary results show that spray-dried microspheres based on MPC could be a suitable nasal delivery 
system for the administration of metoclopramide. 
Rajesh R. Parikh et al.37  The objective of this research was to optimize the processing parameters for 
poly(D,L-lactide-co-glycolide) (PLGA) microspheres of 5-fluorouracil (5-FU) and to mathematically 
relate the process parameters and properties of microspheres. Microspheres were prepared by a water-in-
oil-in-water emulsion solvent evaporation technique. A 3
2 
factorial design was employed to study the 
effect of the volume of the internal phase of the primary emulsion and the volume of the external phase of 
the secondary emulsion on yield, particle size, and encapsulation efficiency of microspheres. An increase 
in the volume of the inter-nal phase of the primary emulsion resulted in a decrease in yield and 
encapsulation efficiency and an increase in particle size of microspheres. When the volume of the external 
phase of the secondary emulsion was increased, a decrease in yield, particle size, and encapsulation 
efficiency was observed. Micro-spheres with good batch-to-batch reproducibility could be produced. 
Scanning electron microscopic study indicated that microspheres existed as aggregates. 
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Munday D L et al.38  The utility of two novel linear random copolyesters to encapsulate and control the 
release of ibuprofen, via microspheres, was investigated. Various manufacturing parameters, including 
temperature, disperse phase volume and polymer ibuprofen ratios were altered during the microsphere 
production. The effects of these changes on the morphological characteristics of the microspheres, yield, 
drug loading, encapsulation efficiency and drug release rates were examined. The diameter of the 
microspheres ranged from 36 to 89 _m and showed both smooth and ridged surfaces. Microsphere 
diameter was probably determined by the internal phase volume, while surface morphology was 
controlled by manufacturing temperature. Greater encapsulation efficiency was obtained by increasing the 
polymer: ibuprofen ratio and by reducing the internal phase volume. For all batches there was an initial 
burst drug release into phosphate buffer (pH 7.4) over the first 2–4 hr, which was followed by a much 
slower release rate over the remaining time period. Drug release rates during both these phases were 
dependent upon the amount and nature of the polymer in the microspheres, noting that the more 
hydrophilic polymer provided faster release rates.  
Ibuprofen solubility appeared to play a dominant role in controlling release, although both encapsulation 
efficiency and microsphere morphology were also contributing factors. 
Patel V et al.39  Magnetic microsphere is newer approach in pharmaceutical field. Magnetic microsphere 
is prepared by various techniques. It is having various applications in diagnosis and 
treatment of various diseases. Microspheres are characteristically free flowing powders consisting of 
proteins or synthetic polymers which are biodegradable in nature and ideally having a particle size less 
than 200ȝm. A well designed controlled drug delivery system can overcome some of the problems of 
conventional therapy and enhance the therapeutic efficacy of a given drug. In future by combining various 
other strategies, microspheres will find the central place in novel drug delivery, particularly in diseased 
cell sorting, diagnostics, gene & genetic materials, safe, targeted and effective in vivo delivery and 
supplements as miniature versions of diseased organ and tissues in the body. 
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Dolores Blanco M et al.40   Polymeric microsphere degradation must be taken into account in the design 
of drug delivery systems to be injected in in vivo systems, thus a prior analysis of in vitro degradation 
behavior of microspheres appears to be necessary. In this study degradation characteristics of poly 
(lactideco-glycolide) (PLGA) and poly (d, l-lactide) (PLA) microspheres prepared by the spray-drying 
technique have been examined. It was found that a slow decrease in molecular weight took place during 
the first stage of degradation, and the value of the rate constant decreased with the increase of the 
percentage of lactic acid of the polymer in a linear way. Thus, the period of time of this first stage 
decreased with the increase of content of glycolidyl units of the polymer, and it was the unique stage 
observed in PLA microspheres after 5 months of study. 
During this period of time, significant mass loss was not observed in the microspheres. The second stage 
of degradation of PLGA microspheres showed a larger rate constant, whose value increased with the 
content of glycolidyl units of the polymer. Mass loss was observed from number-average molecular 
weight about 6000. A sharp decrease of glass transition temperature (Tg) was observed coinciding with 
the start of mass loss. This fact was accompanied by a physical change of the samples, fusion of 
microspheres to form large particles, which also fusion to form a unique mass of polymer; moment from 
that the degradation process was quicker. 
Sahu S et al.41  The development of oral sustained or controlled release dosage form of captopril has been 
an interested topic of research for a long period of time. Difficulties encountered on the fact that the drug 
is freely water soluble. Such drug is difficult to be delivered orally in a sustained or controlled release 
manner and, Due to its effectiveness and intensive use as a drug of choice in the treatment of hypertension 
and congestive heart failure, numerous sustained and controlled release formulations of captopril have 
been made and reported. Captropril microsphere were prepared with a coat consisting of alginate and 
polymer such as HPMC, Sodium alginate, Sodium Carboxy methyl cellulose, by Ionic cross linking 
technique using CaCl2.  
 
 
     Page 43 of 118 
     
5.DRUG PROFILE 
Generic name :  Domperidone 
Class   : A specific blocker of dopamine receptors 
Structure 
                  
Chemical Name : 5-Chloro-1-[1-[3-(2,3-dihydro-2-oxo-1H benzimidazol-1-  yl) 
    propyl]-4-piperidinyl]-1,3-dihydro-2H-benzimidazol-2- one 
Molecular formula : C22H24ClN5O2 
Molecular weight : 425.911 
Description  : White or almost white crystalline powder  
Melting point  : 240°c - 242°c  
Half life  : 4 - 5 hrs 
Solubility  : Very slightly soluble in water and alcohol, slightly soluble in 
methanol ,sparingly soluble in dimethylformamide. 
Standards  : Domperidone contains NLT 98.5 % and NMT 101.0 % of 
 C
8
H
15
N
7
O
2
S
3 
calculated on dried basis. 
Heavy metal  : Not more than 10 ppm 
Sulphated Ash : Not more than 0.1 %,  
Loss on drying : It loses not more than 0.5 % W/W. 
     Page 44 of 118 
     
Pharmacological profile:  Domperidone is a third generation β receptor antagonist that has a 
unique pharmacological profile. It blocks β1, β2 and α1 receptors. It also has antioxidant and ant 
proliferative effects. It has membrane-stabilizing activity but it lacks intrinsic sympathomimetic activity. 
Domperidone produces vasodilatation. 
 
Mechanism of action: Domperidone acts as a gastrointestinal emptying (delayed) adjunct and 
peristaltic stimulant. The gastro-prokinetic properties of domperidone are related to its peripheral 
dopamine receptor blocking properties. Domperidone facilitates gastric emptying and decreases small 
bowel transit time by increasing esophageal and gastric peristalsis and by lowering esophageal sphincter 
pressure. It has strong affinities for the D2 and D3 dopamine receptors, which are found in the 
chemoreceptor trigger zone, located just outside the blood brain barrier, which - among others - regulates 
nausea and vomiting.. 
 
                                                 
Pharmacokinetic Parameters 
Bio availability 25– 30 % 
Plasma half life 4-6hr(oral),3.5hr 
(parenteral) 
Plasma protein binding 91%-93% 
Excretion Renal (33%), Feces 
(66%) 
Table: 1 
Interactions: Domperidone with Artemether, Ziprasidone, Tacrolimus, Thiothixene gives Additive QTc-
prolongation may occur. It is also known to interact with other drugs like cabergoline, cinnarizine, 
lisuride, oxycodone, pergolide, piribedil.  
Food Interactions: Take 15 to 30 minutes before meals to avoid food interactions 
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Adverse effects: The severe or irreversible adverse effects of Domperidone, which give rise to further 
complications include Tardive dyskinesia, Parkinsonism, Extrapyramidal dystonic reactions. 
Domperidone produces potentially life-threatening effects which include seizures, dysrhythmias, which 
are responsible for the discontinuation of Domperidone therapy. The signs and symptoms that are 
produced after the acute overdosage of Domperidone include Convulsions, Coma, GI disturbances, and 
Extra pyramidal effects.  
Therapeutic use 
 There is some evidence that Domperidone has antiemetic activity 
 Domperidone has also been found effective in the treatment of gastro paresis, a stomach motility 
condition and for pediatric-gastro esophageal reflux 
 It can be used in patients with Parkinson's disease. 
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POLYMER PROFILE 
PECTIN 
Source  :  Inner portion of rind of citrus peel i.e. citrus simon or  
citrus aurantium (Rutaceae)  
Synonyms  :  Citrus pectin, Poly(1,4-alpha-D-galacturonide) 
Structure: 
   
 Chemical name : Poly(1,4-alpha-D-galacturonide) 
Molecular weight : 60–130,000 g/mol 
Description  : It is an odorless and mucilaginous, Cream –yellowish powder. 
Moisture content : Pectin absorbs moisture from the atmosphere, the amount of water 
 absorbed depends upon  initial moisture content and temperature 
 and relative humidity of surrounding air.  
Solubility  : Pectin is soluble in pure water, partially soluble in cold water.  
It is insoluble in alcohol and organic solvents. When pectin is mixed 
with alcohol or organic solvent and mixed with water it is soluble, 
whereas di- and tri- salts are weakly soluble or insoluble. 
Viscosity  : Typical viscosity values for 1 % (w/v) aqueous solutions of Pectin 
viscosities measured at 10ºC. Above 70º the final viscosity is 
slightly reduced 
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TYPICAL PROPERTIES 
Acidity/alkalinity 2-8 
Bulk density 580 - 600gms/lit 
gel strength 90 – 110 
Ash Not more than 4% 
Loss on drying Not more than 10% 
Table: 2 
Functional Category:    Pectin has excellent, Gelling agent, Emulsifying and thickening,  rate-controlling 
polymer for sustained release, stabilizing agent, tablet binder and viscosity- increasing agent. 
Applications: 
 Pectin is used as a thickening and stabilizing agent. 
  It helps to prevent oil separation by stabilizing the emulsion, although it is not an emulsifier 
 Pectin is also an ingredient in some sustained-release pills. 
 It is also used as a suspending and thickening agent in topical formulations, particularly 
ophthalmic preparations.  Pectin used as adsorbent in treatment of diarrhea. 
 It used as haemostatic for internal or external hemorrhage. 
 It used as emulsifying agent, gelling agent in acidic medium and as plasma substitute. 
 Used as thickening agent in sauces, jams, ketchups. 
 It is more stable in acidic medium. Pectin in combination with gelatin used as encapsulating agent 
for sustained release. 
 In the cigar industry, pectin is considered an excellent substitute for vegetable glue 
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Stability: Pectin is a stable material, although it is hygroscopic after drying. Pectin is stable at 
ordinary conditions, becomes unstable in excess heat. Pectin is combustible at higher temperatures, 
because of this it must be kept away from heat and any source of ignition. Viscosity, solubility and 
gelation are generally related (e.g. factors that increase gel strength will increase the tendency to gel, 
decrease solubility, and increase viscosity and vice versa At a pH of 5-6 low methylated pectin is stable, 
but high methoxylated pectin is stable only at room temperature  
Incompatibilities: Pectin is incompatible with some oxidizing agents. Since it is nonionic, will not 
complex with metallic salts or ionic organics to form insoluble precipitates. Decomposition by oxides of 
carbon 
Safety: The FAO/WHO joint Expert Committee on Food Additives and in the EU, no numerical 
acceptable daily intake (ADI) has been set, as pectin is considered safe. In the US, pectin is GRAS –
 generally recognized as safe. In most foods it can be used according to good manufacturing practices in 
the levels needed for its application (quantum satis). 
In the International Numbering System (INS), pectin has the number 440. In Europe, pectin’s are 
differentiated into the E numbers E440 for non-amidated pectin’s and E440. There are specifications in all 
national and international legislation defining its quality and regulating its use. 
Handling precautions:   Pectin dust cause mechanical irritation to the eyes and eye protection is 
recommended. Excessive dust generation should be avoided to minimize the risk of explosion in air. It 
causes skin irritation or injury. Decomposition caused by Irritating and toxic fumes and gases.  So wear 
safety glasses with side shields and appropriate gloves to prevent eye and skin exposure respectively 
 
 
 
 
     Page 49 of 118 
     
XANTHANGUM 
Synonyms  : Bacterial Polysaccharide, Corn Sugar Gum, Goma Xantana,  
Gomme de Sucre de Maïs, Polysaccharide de Type Xanthane, 
Polysaccharide Xanthane, Xanthan, Xanthomonas campestris. 
Structure 
  
Molecular formula : C35H49O29 (monomer) 
Molecular weight : 2×106 to 5×107  
Description  : It is an odorless and tasteless, light beige powder. 
Moisture content : Xanthun gum absorbs moisture from the atmosphere. The amount of 
water absorbed depends upon the initial moisture content and the 
temperature and relative humidity of the  surrounding air. 
Solubility  : It is soluble in cold water, forming a viscous colloidal solution and 
 practically insoluble in organic solvents 
Viscosity  : Typical viscosity values for 1 % (w/v) aqueous solutions of 
Xanthun gum viscosities measured at 10ºC. Above 80º the final 
viscosity is slightly reduced. 
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TYPICAL PROPERTIES 
Acidity/alkalinity pH = 6-8 
Density 1.5 g/cm3 (20 C) 
Bulk density 550 - 700kg/m³ 
Moisture 13% max 
Ash 13% max 
Table: 3 
Functional Category: Xanthangum has excellent thickening, stabilizing, pseudoplastic property 
and Emulsifying rate-controlling polymer for sustained release stabilizing agent, tablet binder and 
viscosity-increasing agent. 
 Applications: 
 Xanthan gum is used as a thickening and stabilizing agent in foods, toothpastes, and medicines.  
  It helps to prevent oil separation by stabilizing the emulsion, although it is not an emulsifier 
 Xanthan gum is also an ingredient in some sustained-release pills. 
 It is also used as a suspending and thickening agent in topical formulations, particularly 
ophthalmic preparations.  
  Use as a bulk-forming laxative to treat constipation. 
  Lowering blood sugar in people with diabetes. 
 Use as a saliva substitute for dry mouth. 
 In the oil industry, xanthun gum is used in large quantities, usually to thicken drilling mud. 
 In cosmetics, xanthan gum is used to prepare water gels, usually in conjunction 
with bentonite clays. 
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     Stability: Xanthun gum powder is a stable material, although it is hygroscopic after drying. Stability is 
affected by solute concentration, temperature (both the dissolving temperature and the measured solution 
temperature), salinity and PH value.  
Xanthun gum shows high low-shear viscosity but is strongly shear-thinning. Being non-ionic, it is not 
affected by ionic strength or pH but will degrade at pH extremes at temperature. 
 
Incompatibilities: Xanthun gum is incompatible with some oxidizing agents. Since it is nonionic, it 
will not complex with metallic salts or ionic organics to form insoluble precipitates.  
Safety:  The safety data on guar gum may be largely available to establish the safety. Xanthan gum 
is safe when up to 15 grams per day are taken. It can cause some side effects such as intestinal gas 
(flatulence) and bloating. The safety of Xanthun gum has been assessed by JECFA (Joint Expert 
Committee on Food Additives) in 1955 and by the EEC’s SCF (European Economic Community, 
Scientific Committee on Foods) in 1964. In USA, guar gum has been considered GRAS (Generally 
Recognized As Safe) since 1984 in numerous food applications.  
Guar gum did not elicit measurable mutagenic responses. This material is a dust or may produce 
dust. Breathing small amounts of this material is not likely to be harmful. Unlikely to cause skin irritation 
he Food and Drug Administration issued a caution that simply thick should not be fed to premature infants 
because it may cause necrotizing enterocolitis. 
Handling precautions: Xanthun gum dust may be irritant to the eyes and eye protection is recommended. 
Excessive dust generation should be avoided to minimize the risk of explosion in air. Unlikely to cause 
skin irritation or injury. This material is a dust or may produce dust. Breathing small amounts of this 
material is not likely to be harmful. 
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GUARGUM 
Synonyms  : Guar, guar flour, jaguar gum, guaran. 
Structure 
                    
  Molecular weight  : 2,000 to 3,000 mPa·s 
Description                 : It is an odorless and tasteless, yellowish white coloured  
powder. 
Moisture content  : Guar gum absorbs moisture from the atmosphere the amount 
of water absorbed depends upon the initial moisture  
content and the temperature and relative humidity of t 
surrounding air.  
Solubility   : It is soluble in cold water, forming a viscous colloidal 
solution and also in hot water and practically insoluble in 
organic solvents. 
Viscosity   : Typical viscosity values for 2 % (w/v) aqueous solution of  
Guar gum viscosities measured at 20ºC. Above 80º the final 
viscosity is slightly reduced 
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Table: 4 
Functional Category: Guar gum  has strong hydrogen bonding properties. It has excellent 
thickening, Emulsion, Stabilizing and film forming properties, rate-controlling polymer for sustained 
release, stabilizing agent, tablet binder and viscosity-increasing agent. 
Applications  
Guar gum is widely used in oral and topical pharmaceutical formulations.  
 It is also used as a suspending and thickening agent in topical formulations, particularly 
ophthalmic preparations. 
 As a protective colloid, it can prevent droplets and particles from coalescing or agglomerating, 
thus inhibiting the formation of sediments. 
 Solutions with different gum concentrations can be used as emulsifiers and stabilizers because they 
prevent oil droplets from coalescing. Guar gum is also used as suspension stabilizer 
TYPICAL PROPERTIES 
Acidity/alkalinity pH = 3-7.0 for a 1 % w/w aqueous solution 
Ash Not more than 1% 
Auto ignition temperature 360ºC 
Density (bulk) 0.321 g/cm3 
Density (tapped) 0.537 g/cm3 
Density (true) 1.316 g/cm3 
Specific gravity 1.26 
 
Melting point 
Browns at 190–200 ºC. 
Chars at 225–230 ºC. 
Glass transition temperature is 170–180 ºC. 
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 It is 5 to 8 times ticking power than starch. 
 It used as protective colloid, binding agent, bulk laxative, appetite depressant and used in peptic 
ulcer therapy. 
 It is also used in cosmetic preparation. 
Stability: Guar gum powder is a stable material, although it is hygroscopic after drying. Guar gum 
shows high low-shear viscosity but is strongly shear-thinning. Being non-ionic, it is not affected by ionic 
strength or pH but will degrade at pH extremes at temperature for e.g. pH 3 at 50°C. With case in, it 
becomes slightly thixotropic forming a biphasic system containing casein micelles. 
 
Incompatibilities: Guar gum is incompatible with some oxidizing agents. Since it is nonionic, will not 
complex with metallic salts or ionic organics to form insoluble precipitates. 
Safety: The safety data on guar gum may be largely available to establish the safety of its partially 
hydrolyzed analogue, PHGG. The safety of guar gum has been assessed by JECFA (Joint Expert 
Committee on Food Additives) in 1975 and by the EEC’s SCF (European Economic Community, 
Scientific Committee on Foods) in 1978. In USA, guar gum has been considered GRAS (Generally 
Recognized As Safe) since 1974 in numerous food applications. Guar gum did not elicit measurable 
mutagenic responses in the host-mediated assay using Salmonella, and was not carcinogenic in either 
species or sex 
Handling precautions: Guar gum dust may be irritant to the eyes and eye protection is recommended. 
Excessive dust generation should be avoided to minimize the risk of explosion. Guar gum is combustible. 
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6.MATERIALS &METHODS 
 
METHODOLOGY 
PREFORMULATION STUDY 
Preformulation testing is an investigation of physical and chemical properties of drug alone and when 
combined with excipients. It is the first step in the rational development of dosage form. 
Preformulation studies relate to pharmaceutical and analytical investigation carried out in supporting 
formulation development efforts of dosage form. 
The following preformualtion studies were for the sample of drug. 
 
Organoleptic Properties of Drug Powder: 
Colour and nature:   
Transferred small quantity of the sample on a white piece of paper to spread powder and examined 
visually. 
Physical characteristics of drug powder: 
Flow properties: 
a) Bulk density (Db):  It is the ratio of powder to bulk volume.  The bulk density depends on 
particle size distribution, shape and cohesiveness of particles. Accurately weighed quantity of powder 
was carefully poured into graduated measuring cylinder through large funnel and volume was measured 
which is called intial bulk volume. Bulk density is expressed in gm/cc and is given by,         
                                          Db = M / Vo 
Where, Db = Bulk density (gm/cc), 
M = mass of powder (g),  
Vo =bulk volume of powder (cc). 
b) Tapped density(Dt):  
Ten grams of powder was introduced into a clean, dry 100ml measuring cylinder. The cylinder was 
then tapped 100 times from a constant height and tapped volume was read. It is expressed in gm/cc and  
is given by, 
                              Dt = M / Vt 
 
 Where, 
            Dt
 = Tapped density(gm/cc),            
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            M  = mass of powder (g), 
             Vt  = tapped volume of powder (cc). 
 
c) Angle of repose(θ):  
It is defined as the maximum angle possible between the surface of pile of the powder and the 
horizontal plane. Fixed funnel method was used. A funnel was fixed with its tip at a given height (h), 
above a flat horizontal surface on which a graph paper was placed. Powder was carefully poured 
through a funnel till the apex of the conical pile just touches the tip of funnel. The angle of repose was 
then calculated using the formula, 
                                                θ =tan1(h/r) where, θ = 
angle of repose 
            
h = height of pile
 
                       r = radius of the base of the pile. 
 
 
 
 
 
 
 
Table 05: Scale of Flowability 
 
 
 
 
 
d) Percentage Compressibility (or) Carr’s index (%): 
   Based on the apparent bulk density and the tapped density, the percentage   
  Compressibility of the bulk  drug was determined  by the fo l lowing  formula. 
 
Carr’s index (%) = [(Tapped Density-Bulk Density) / Tapped Density] X 100 
 
Compressability index 
 
Flow characteristics Hausner ratio 
<10 Excellent 1.00-1.11 
11-15 Good 1.12-1.18 
16-20 Fair 1.19-1.25 
21-25 Passable 1.26-1.34 
26-31 Poor 1.35-1.45 
32-37 Very poor 1.46-1.59 
>38 Very very poor >1.60 
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S.No %Compressibility Flow ability 
1 5-12 Excellent 
2 12-16 Good 
3 18-21 Fair 
4 23-25 Poor 
5 33-38 Very poor 
6 More than40 Very very poor 
 
Table 06: % Compressibility limits with respect to flowability 
 
e) Hausner’s Ratio:   It indicates the flow properties of powder and is measured by the ratio of tap 
density to bulk density. 
 
Hausner ratio  = Tapped density/Bulk density 
 
  Table 07: Hausner ratio limits. 
 
Hausner’s ratio Type of flow 
< 1.25 Good flow 
> 1.25 Poor flow 
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     EXPERIMENTAL 
LIST OF CHEMICALS: 
 
S.No 
 
            Chemicals  used          Suppliers 
1 Domperidone 
 
Yarrow chemical products, Mumbai 
 
2 Xanthun gum 
 
Sd Fine Chem limited, Mumbai. 
 
3 Pectin Nice chemicals pvt ltd, Mumbai. 
 
4 Calcium Chloride Finar chemicals limited, Mumbai. 
 
5 Guar gum Sd Fine Chem limited, Mumbai. 
 
 
Table: 8 
LIST OF EQUIPMENTS: 
 
Table: 9 
 
S.No 
 
Equipments used 
 
         Suppliers 
1 
 
 
Magnetic  Stirrer 
 
     
Model:  MS: 5OO, Remi 
Electronics Limited. 
 
2  UV-Spectrophotometer 
Model: UV – VIS double beam 
spectrophotometer,  Labomed inc 
3  Dissolution Apparatus 
 
Model No: 2202,Systronics 
4 
 
 
Hot air Oven 
 
 
Model No: 912, Electronics 
5 
 
Scanning Electron Microscopy 
 
 
NOVEX 
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              ANALYTICAL METHODOLOGY 
Development of UV spectroscopic method 
Determination of absorption maxima: Absorption maxima or the wavelength at which absorption takes 
place for accurate analytical work  is important to determine the absorption maxima of the substance 
under study. 
Method: UV method 
Equipments: UV-VIS spectrophotometer 
100mg of domperidone was dissolved in 100ml methanol. 1ml of this solution was pipette out in 
separate volumetric flask and diluted with phosphate buffer 7.4 and subjected for UV scanning in the 
range of 200-800 using Double beam UV-VIS spectrophotometer, (pharmaspec-1700, shimadzu, japan). 
The absorption maxima obtained at 284nm with a characteristic peak. 
Preparation of calibration curve: Using this absorption maxima a standard curve was prepared in the 
concentration range of 2-10 µg/ml. 
Method: UV method 
Equipments: Double beam UV-VIS spectrophotometer. 
Reagents: Methanol, phosphate buffer pH 7.4, domperidone. 
For the preparation of calibration curve stock solution was prepared by dissolving 100mg of 
accurately weighed domperidone in 100ml of methanol. Further 1ml of this solution was pipette into 1 
00ml of volumetric flask and diluted to 100ml with phosphate buffer7.4 solution.  
From this pipette out 2,4,6,8 and 10ml into a series of 10ml volumetric flask and was made up to 
10ml with phosphate buffer pH7.4 to get 2,4,6,8 and 10µg/ml of domperidone respectively . The optical 
density values of resulting solutions were measured at 284nm and recorded in the table with statistical 
data in table 7. Concentration versus optical density values are plotted and given in the figure1. 
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S.No. Time in hours Absorbance 
1 
0 0 
2 
2 0.033 
3 
4 0.064 
4 
6 0.092 
5 8 0.123 
6 
10 0.154 
 
Table 10: Calibration curve data for domperidone 
 
 
 
 
 
 
 
 
 
Fig: 1 STANDARD GRAPH OF DOMPERIDONE 
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Preformulation studies 
 Preformulation testing is the first step in the rationale development of dosage forms of a drug 
substance. It can be defined as an investigation of physical and chemical properties of a drug substance 
alone and when combined with excipients. The overall objective of preformulation testing is to generate 
information useful to the formulator in developing stable, efficacious and safe dosage form. 
Hence preformulation studies were carried out on the obtained samples of drug for identification and 
compatibility studies. 
 Identification of Drug: 
The obtained sample was examined by infrared absorption spectral analysis and was compared 
with the reference standard IR spectrum of domperidone.  
        Method: IR Spectra of drug and drug-excipients blends were recorded on an IR spectrophotometer 
(Shimadzu Corporation, Japan) in the range of 4000-400 Cm-1 using potassium bromide discs 
 Determination of Melting point 
Melting point of domperidone was determined by open capillary method.  Melting-point 
apparatus is most often used for the determination of the melting point of a solid. A few crystals of 
the compound are placed in a thin walled capillary tube 10-15 cm long, about 1 mm in inside 
diameter and closed at one end. 
 Determination of solubility 
The known excess amount of drug was added to 5 ml of water, phosphate buffer pH6.8, methanol 
and DMSO and these samples were rotated at 20 rpm in a water bath (37 ± 0.5°C) for 2hours. The 
samples were then filtered through 0.45 ȝm membrane filter, suitably diluted, and analyzed 
visually. 
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 Compatibility Studies 
The compatibility of drug and polymers under experimental condition is important prerequisite before 
formulation. Incompatibility between drugs and excipients can alter stability and bioavailability of drugs, 
thereby, affecting its safety and/or efficacy. Study of drug–excipients compatibility is an important 
process in the development of a stable solid dosage form. Drug–excipients compatibility testing at an early 
stage helps in the selection of excipients that increases the probability of developing a stable dosage form. 
 
 Scanning electron microscopy (SEM): 
Scanning Electron Microscopy - SEM - is a powerful technique in the examination of materials. It is 
used widely in metallurgy,geology, biology and medicine. SEM is operated under high vacuum the 
specimens that can be studied must be compatible with high vacuum (~ 10-5 mbar). This means that 
liquids and materials containing water and other volatile components cannot be studied directly. Also fine 
powder samples need to be fixed firmly to a specimen holder substrate so that they will not contaminate 
the SEM specimen chamber. Non-conductive materials need to be attached to a conductive specimen 
holder and coated with a thin conductive film by sputtering or evaporation. Typical coating materials are 
Au, Pt, Pd, their alloys, as well as carbon. There are special types of SEM instruments such as variable-
pressure SEM (VPSEM) and environmental 
 SEM (ESEM) that can operate at higher specimen chamber pressures thus allowing for non-
conductive materials (VP-SEM) or even wet specimensto be studied (ESEM). All SEM images are in 
black-and-white, although they may subsequently have false colours applied to them for aesthetic reasons 
or to aid interpretation. 
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                                       Picture of Scanning Electron Microscopy. 
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SEM analysis was performed to identify themorphology. The samples were coated with gold 
 
 using Hummer sputter coater (Techniques, Ltd.), then carried using a Jeol JSM-840 scanning 
 
 electron microscope (Jeol USA, Inc.,Peabody, MA), and captured the images using a digital  
 
capture cardand Digital Scan Generator 1 (Jeol). SEM can provide information on  surface 
 
 topography, crystalline  structure, chemical composition  and electrical behaviour of the top 
  
1 urn or so of specimen. Scanning electron microscopy can provide a variety of imaging  
 
techniques with resolutions in the range 1 pm to 1 nm,  depending on the microscope  and the 
 
 signal used to form the image. 
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PREPARATION OF MICROPARTICLES 
 
          Microparticles of Domperidone were prepared by ionic gelation technique. Accurately weighed 
quantity of drug was dissolved in sufficient quantity of distilled water. In another beaker, suitable amount 
of pectin was taken and mixed well with 20 ml of water. The drug solution was added to the polymer 
solution with stirring to produce viscous form.       
                  The drug solution is to be mixed with all the three polymers that are used in the formulations 
according to the ratios mentioned in the protocol. 
                Then polymer drug solution was added drop wise by using syringe of 22 G in diameter from a 
height of about 5cms into a beaker containing 4% w/v solution of calcium chloride with continuous 
stirring by magnetic stirrer. Then the solution was filtered by using whatmann filter paper no-1. The 
microparticles were washed with water and stored in well-closed container for further use. 
                                 
Picture of Microparticles 
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LIST OF MICROPARTICLES OF DOMPERIDONE 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Table: 11 
 
 
 
 
S.NO 
 
FORMULATION 
CODE 
DRUG:POLYMER         
RATIO(domperidone:
pectin:guar gum: 
xanthun gum) 
 
BATCH SIZE(mg) 
DRUG+POLYMER 
   
  1. 
    
              F1 
 
1:1:0:0 
 
50+100 
  
  2. 
          
              F2 
 
1:2:2:0 
 
50+200+200 
 
  3. 
 
              F3 
 
1:2:4:0 
 
50+200+400 
 
4. 
 
 
              F4 
 
1:4:2:0 
 
50+400+200 
 
5. 
 
              F5 
 
1:4:2:4 
 
50+0+0200+200 
 
6. 
 
              F6 
 
1:0:4:2 
 
50+0+400+200 
 
7. 
 
              F7  
 
1:2:2:4 
 
50+0+200+400 
 
8. 
 
              F8  
 
1:2:0:2 
 
50+200+0+200 
 
9. 
 
             F9 
 
1:1:0:2 
 
50+100+0+200 
 
10. 
 
            F10 
 
1:2:0:1 
 
50+200+0+100 
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EVALUATION OF MICROPARTICLES 
Swelling studies: 
    A known weight (50 mg) of microparticles were placed in little excess of distilled water, 0.1N Hcl and 
PBS (pH 7.4) and allowed to swell to constant weight. The microparticles were removed, blotted with 
filter paper and their changes in weight were measured at certain intervals and recorded. The degree of 
swelling (a) was then calculated from the formula: 
                                           a  =  Wg-Wo / Wo 
                             where, Wo =  initial weight of the beads  
                                         Wg = Weight of beads/microparticles at equilibrium          
                                                   swelling in medium. 
Entrapment efficiency: 
    Drug entrapment efficiency of Domperidone microparticles was performed by accurately weighing 50 
mg of microparticles and suspended in 100ml of PBS of pH7.4 and it was kept aside for 24 hours. Then, it 
was stirred for 15 mins and filtered. After suitable dilution, Domperidone content in the filtrate was 
analyzed spectrophotometrically at 284 nm using U.V. spectrophotometer. 
              Entrapment Efficiency = Eୱ୲୧୫a୲ୣୢ ୢ୰୳୥ ୡ୭୬୲ୣ୬୲T୦ୣ୭୰୧୲୧ୡa୪ ୢ୰୳୥ ୡ୭୬୲ୣ୬୲×100 
 Percentage yield:  
The total amount of microparticles obtained was weighed and the percentage yield calculated by 
taking into consideration the weight of the drug and  polymer. 
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Particle size analysis:  
Different sized microparticles were determined by using calibrated eye piece micrometer and stage 
micrometer. The average size of the particles is determined by   
                                                       D avg = End/ En 
Drug content:  
Microparticles equivalent to 50mg were accurately weighed and transferred to 50ml volumetric 
flask. Solvent was added to dissolve the microparticles and made up to the mark with same solvent. From 
this, further suitable dilutions were made and the drug content analyzed by UV spectrophotometrically at 
284 nm. 
In vitro Dissolution Studies: 
     The release of Domperidone from microparticles was investigated in pH 1.2 buffer and Phosphate 
buffer of pH 7.4 as a dissolution medium (900 ml.) using the rotating basket method specified in 
USPXXIV (model TDT6P Electro lab). Sample of 100 mg microparticles were taken in the basket. 
       A speed of 75 rpm and temperature 37± 0.5°C was maintained throughout the experiment. At fixed 
intervals aliquots (5 ml) was withdrawn and replaced with fresh dissolution media. The concentration of 
drug released at different time intervals was then determined by measuring the absorbance using the U.V. 
spectrophotometer at 475 nm against balance. 
 
 
 
 
 
     Page 69 of 118 
     
KINETICS OF DRUG RELEASE: 
      To study the study kinetics, data obtained from in vitro release were plotted in various kinetic models. 
Zero order equation: 
The graph was plotted as % drug released Vs time in hours. 
                  C=K0t 
Where,     K0 = Zero order constant in concentration/time 
                 t =Time in hours 
The graph would yield a straight line with a slope equal to K0 and intercept the origin of the axis. The 
results were tabulated and graph was shown.  
First order equation:  
The graph was plotted as log % cumulative drug remaining Vs Time in hours. 
            Log C = log C0- Kt /2.303 
Where, C0 = initial concentration of drug.  
             K= First order constant. 
              t=Time.  
Higuchi kinetics: 
The graph was plotted as % Cumulative drug released Vs square root of time. 
              Q = Kt 1/2 
Where, K = constant reflecting design variable system.  
             t =time in hours 
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         Hence drug release rate is proportional to the reciprocal of square root of time. If the plot yields a 
straight line and the slope is one, then the particular dosage form is considered to follow Higuchi kinetics 
of drug release. The results were tabulated. 
Korsemeyer – Peppas equation:  To evaluate the mechanism of drug release, it was further plotted 
in Peppas equation as log cumulative % of drug released Vs time 
                 Mt / Mα = Kt n  
                Log Mt / M α = log K + n log t 
Where, Mt / Mα =fraction of drug released at time t 
                        t =Release time 
 K = Kinetic constant (incorporating structural and geometric characteristics of preparation) 
n = Diffusional exponent indicative of the mechanism drug release. 
        If n value is 0.5 or less, the release mechanism follows “ Fickian diffusion” and higher values of 0.5 
< n< 1 for mass transfer follow a non- fickian model (anamalous transport). The drug release follows zero-
order drug release and case – II transport if the value is 1. For the values of n higher than 1, the 
mechanism of drug release is regard as super case II transport. This model is used to analyze the release of 
pharmaceutical polymeric dosage forms when the release mechanism is not known or more than one type 
of release phenomenon was involved. The n value could be obtained from slope of the plot of log 
cumulative % of drug released Vs log time. The results were tabulated.  
 Zero Order Reaction - % Cumulative drug release Vs Time in hours  
 Korsmeyer – Peppas equation - log cumulative % of drug released Vs log time 
 Higuchi kinetics       - % Cumulative drug release Vs square root of time  
 First Order Reaction – Log % Cumulative drug remaining Vs Time in hours  
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7.RESULTS &DISCUSSIONS 
A successful attempt was made to formulate domperidone microparticles using different polymers. 
Effect of polymers applied on formulations was assessed. In the present work ten formulations were 
prepared whose composition is mentioned in Table 8. The formulated microparticles were characterized 
for various physicochemical parameters. 
 
PREFORMULATION STUDIES OF PURE DRUG: 
Identification of Domperidone: 
The IR spectrum of pure drug was found to be similar to that of standard spectrum of 
Domperidone. The spectrum of Domperidone shows the following functional groups N ─ H, C ─ H, C ═ 
O, C ─ N  at their frequencies shown in 3360 cm-1, 3104 cm-1, 1708 cm-1, 1675 cm-1. 
 
Determination of melting point 
The melting point of Domperidone was found to be 241ºC which complied with the BP standards. 
 
Determination of solubility 
Solubility of Domperidone in various solvents reveals that it was slightly soluble in alcohol, freely 
soluble in dimethyl sulfoxide and soluble in methylene chloride, methanol. Practically insoluble in water 
and in dilute acids. Sparingly soluble in ethyl ether. 
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Drug - polymer Compatibility Studies: 
 Compatibility studies of pure drug Domperidone with polymers were carried out prior to the 
formulation of microparticles. IR spectra of pure drug and polymers were taken, which are depicted in 
Figures 2, 3, 4. All the characteristic peaks of Domperidone were present in spectra at respective 
wavelengths. Thus, indicating compatibility between drug and polymers. It shows that there was no 
significant change in the chemical integrity of the drug. 
  
 
 
Figure 2: FTIR Spectrum of Pure Drug 
 
PECTIN PELLET 26/06/2013 4:25:55PM 
 
 
 
 
 
 
 
 
Figure 3: FITR Spectrum of Polymer Pectin 
DOMPERIDONE PELLET 26/06/2013 4:25:55PM 
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Figure 4: FTIR Spectrum of polymer Xanthun Gum 
 
FTIR Spectrum of  Drug and Polymers for the Functional Groups assigned 
 
Polymer 
 
Groups assigned 
 
C ═ O stretch N ─ H stretch C ─ H stretch C ─ N stretch 
Domperidone 1708 cm-1 3360cm-1 3104.20cm-1 1675cm-1 
Pectin 1620.13cm-1 3084.12cm-1 2977.53cm-1 1654.17Cm-1 
Xanthun gum 1637.24cm-1 3445.55cm-1 3067.30cm-1 1647.26cm-1 
 
Table: 12 
 
 
 
 
 
XANTHAN GUM PELLET 26/06/2013 4:25:55PM 
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PHYSIOCHEMICAL EVALUATION OF DOMPERIDONE MICROPARTICLES 
 
  Table: 10 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
      
Table : 13 
 
 
 
 
 
 
 
Formulation 
code 
Morphology 
Percentage 
yield(%) 
Entrapment 
efficiency (%) 
Particle size 
(µm) 
F1 
 
Spherical & smooth 40.0 23.1 23.68 
F2 
 
Spherical & smooth 46.0 36.2 23.76 
F3 
 
Spherical & smooth 60.1 53.0 23.71 
F4 
 
Spherical & smooth 80.0 72.8 24.02 
F5 
 
Spherical & smooth 88.83 80.24 24.14 
F6 
 
Spherical & smooth 85.0 73.12 24.30 
F7 
 
Spherical & smooth 88.5 78.3 25.39 
F8 
 
Spherical & smooth 83.23 76.22 23.26 
F9 
 
Spherical & smooth 81.22 74.62 22.23 
F10 Spherical & smooth. 80.42 72.29 21.39 
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Entrapment Efficiency Parameters: 
 
 
Figure 5: Entrapment Efficiency for F1 to F5 Formulations 
 
 
Figure 6: Entrapment Efficiency for F1 to F5 Formulations 
 
 
0
10
20
30
40
50
60
70
80
90
F1 F2 F3 F4 F5
Pe
rc
en
ta
ge
 E
n
tr
a
pm
en
t E
ffi
ci
en
cy
 
Formulation Code 
69
70
71
72
73
74
75
76
77
78
79
F6 F7 F8 F9 F10
Pe
rc
en
ta
ge
 
En
tr
a
pm
en
t E
ff
ic
ie
n
cy
  
Formulation  Code 
     Page 76 of 118 
     
In vitro Dissolution Studies: 
     In vitro dissolution studies of all the formulations of Microparticles of Domperidone were carried out 
in pH 6.8 phosphate buffer. The study was performed for 24 hrs, and cumulative percentage drug release 
was calculated at different time intervals. The invitro drug release profiles for the formulations were 
tabulated in tables 11 to table 20. The plot of time Vs. Cumulative % drug release for formulations F1 to 
F10 were plotted and depicted in Figures 7 and 16. Effects of various polymers and their concentration on 
drug release were studied 
Invitro Dissolution Studies Of Domperidone Microparticles 
 
S.No. 
Time 
(h) 
Abs 
(nm) 
Con. 
µg/ml 
Conc. 
Mg/ml 
Conc.200 
ml 
 
Loss 
 
CLS 
 
CDR 
 
% CDR 
1 1 0.030 0.33 0.03 6.666667 0.00 0.00 6.67 11.17 
2 1 0.039 0.43 0.04 8.666667 0.03 0.05 8.72 14.61 
3 2 0.046 0.51 0.05 10.22222 0.04 0.09 10.32 17.28 
4 4 0.074 0.82 0.08 16.44444 0.05 0.14 16.59 27.80 
5 8 0.091 1.01 0.10 20.22222 0.08 0.23 20.45 34.26 
6 12 0.117 1.42 0.14 28.4 0.10 0.33 28.73 48.14 
7 18 0.133 1.48 0.15 29.55556 0.14 0.47 30.03 50.31 
8 24 0.149 1.66 0.17 33.11111 0.15 0.62 33.73 56.52 
 
Table 14 
 
Figure: 7 
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R² = 0.639 
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Invitro dissolution studies-F1  
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Invitro Dissolution Studies of Domperidone Microparticles: 
 
Table 15 
 
 
Figure: 8 
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Invitro dissoution studies-F2 
S.No
. 
Time 
(h) 
Abs 
(nm) 
Con. 
µg/ml 
Conc. 
Mg/ml 
Conc.200 
ml 
Loss CLS CDR % CDR 
1 1 0.033 0.37 0.04 7.333333 0.00 0.00 7.33 12.29 
2 1 0.052 0.58 0.06 11.55556 0.04 0.05 11.61 19.45 
3 2 0.078 0.87 0.09 17.33333 0.06 0.11 17.44 29.22 
4 4 0.089 0.99 0.10 19.77778 0.09 0.19 19.97 33.47 
5 8 0.110 1.22 0.12 24.44444 0.10 0.29 24.74 41.45 
6 12 0.129 1.42 0.14 28.4 0.12 0.42 28.82 48.28 
7 18 0.145 1.61 0.16 32.22222 0.14 0.56 32.78 54.93 
8 24 0.152 1.69 0.17 33.77778 0.16 0.72 34.50 57.80 
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Invitro Dissolution Studies of Domperidone Microparticles 
S.No
. 
Time 
(h) 
Abs 
(nm) 
Con. 
µg/ml 
Conc. 
mg/ml 
Conc.200 
ml 
Loss CLS CDR % CDR 
1 1 0.045 0.50 0.05 10 0.00 0.00 10.00 16.76 
2 1 0.059 0.66 0.07 13.11111 0.05 0.05 13.16 22.05 
3 2 0.087 0.97 0.10 19.33333 0.07 0.12 19.45 32.59 
4 4 0.099 1.10 0.11 22 0.10 0.21 22.21 37.22 
5 8 0.119 1.32 0.13 26.44444 0.11 0.32 26.77 44.85 
6 12 0.131 1.42 0.14 28.4 0.13 0.45 28.85 48.35 
7 18 0.148 1.64 0.16 32.88889 0.14 0.60 33.49 56.11 
8 24 0.161 1.79 0.18 35.77778 0.16 0.76 36.54 61.22 
 
Table 16 
 
Figure: 9 
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Invitro Dissolution Studies of Domperidone Microparticles 
S.No. Time 
(h) 
Abs 
(nm) 
Con. 
µg/ml 
Conc. 
Mg/ml 
Conc.20
0 ml 
Loss CLS CDR % CDR 
1 1 0.033 0.37 0.04 7.333333 0.00 0.00 7.33 12.29 
2 1 0.059 0.66 0.07 13.11111 0.04 0.05 13.16 22.05 
3 2 0.067 0.74 0.07 14.88889 0.07 0.12 15.00 25.14 
4 4 0.091 1.01 0.10 20.22222 0.07 0.19 20.41 34.20 
5 8 0.112 1.24 0.12 24.88889 0.10 0.29 25.18 42.19 
6 12 0.133 1.42 0.14 28.4 0.12 0.42 28.82 48.28 
7 18 0.151 1.68 0.17 33.55556 0.14 0.56 34.11 57.16 
8 24 0.172 1.91 0.19 38.22222 0.17 0.73 38.95 65.26 
 
Table 17 
 
Figure: 10 
 
 
 
y = 3.404x 
R² = 0.511 
0
10
20
30
40
50
60
70
80
90
0 5 10 15 20 25 30
%
C
D
R
 
Time 
Invitro dissolution studies-F4 
     Page 80 of 118 
     
Invitro Dissolution Studies of Domperidone Microparticles 
S.No. Time 
(h) 
Abs 
(nm) 
Con. 
µg/ml 
Conc. 
Mg/ml 
Conc.200 
ml 
Loss CLS CDR % CDR 
1 1 0.028 0.31 0.03 6.222222 0.00 0.00 6.22 10.43 
2 1 0.039 0.43 0.04 8.666667 0.03 0.05 8.72 14.61 
3 2 0.067 0.74 0.07 14.88889 0.04 0.09 14.98 25.10 
4 4 0.102 1.13 0.11 22.66667 0.07 0.17 22.83 38.26 
5 8 0.119 1.32 0.13 26.44444 0.11 0.28 26.73 44.78 
6 12 0.146 1.42 0.14 28.4 0.13 0.41 28.81 52.86 
7 18 0.169 1.88 0.19 37.55556 0.14 0.56 38.11 63.86 
8 24 0.186 2.07 0.21 41.33333 0.19 0.74 42.08 70.50 
 
Table 18 
 
Figure: 11 
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Invitro Dissolution Studies of Domperidone Microparticles 
S.No
. 
Time 
(h) 
Abs 
(nm) 
Con. 
µg/ml 
Conc. 
Mg/ml 
Conc.200 
ml 
Loss CLS CDR % CDR 
1 1 0.039 0.43 0.04 8.666667 0.00 0.00 8.67 14.52 
2 1 0.052 0.58 0.06 11.55556 0.04 0.05 11.61 19.45 
3 2 0.085 0.94 0.09 18.88889 0.06 0.11 19.00 31.83 
4 4 0.111 1.23 0.12 24.66667 0.09 0.20 24.87 41.67 
5 8 0.139 1.54 0.15 30.88889 0.12 0.33 31.21 52.30 
6 12 0.159 1.42 0.14 28.4 0.15 0.48 28.88 59.57 
7 18 0.176 1.96 0.20 39.11111 0.14 0.62 39.73 66.58 
8 24 0.193 2.14 0.21 42.88889 0.20 0.82 43.71 73.23 
 
Table 19 
 
Figure: 12 
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Invitro Dissolution Studies of Domperidone Microparticles 
S.No. Time 
(h) 
Abs 
(nm) 
Con. 
µg/ml 
Conc. 
Mg/ml 
Conc.200 
ml 
Loss CLS CDR % CDR 
1 1 0.036 0.40 0.04 8 0.00 0.00 8.00 13.40 
2 1 0.051 0.57 0.06 11.33333 0.04 0.05 11.38 19.07 
3 2 0.085 0.94 0.09 18.88889 0.06 0.11 19.00 31.83 
4 4 0.120 1.33 0.13 26.66667 0.09 0.20 26.87 45.02 
5 8 0.155 1.72 0.17 34.44444 0.13 0.33 34.78 58.28 
6 12 0.163 1.42 0.14 28.4 0.17 0.51 28.91 62.39 
7 18 0.176 1.96 0.20 39.11111 0.14 0.65 39.76 66.62 
8 24 0.201 2.23 0.22 44.66667 0.20 0.84 45.51 76.26 
 
Table 20 
                        
Figure: 13 
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Invitro Dissolution Studies of Domperidone Microparticles 
S.No
. 
Tim
e (h) 
Abs 
(nm) 
Con. 
µg/ml 
Conc. 
Mg/ml 
Conc.200 
ml 
Loss CLS CDR % 
CDR 
1 1 0.031 0.34 0.03 6.888889 0.00 0.00 6.89 11.54 
2 1 0.051 0.57 0.06 11.33333 0.03 0.05 11.38 19.07 
3 2 0.078 0.87 0.09 17.33333 0.06 0.11 17.44 29.22 
4 4 0.098 1.09 0.11 21.77778 0.09 0.19 21.97 36.81 
5 8 0.120 1.33 0.13 26.66667 0.11 0.30 26.97 45.19 
6 12 0.147 1.42 0.14 28.4 0.13 0.44 28.84 52.89 
7 18 0.175 1.94 0.19 38.88889 0.14 0.58 39.47 66.13 
8 24 0.189 2.10 0.21 42 0.19 0.77 42.77 71.67 
 
Table 21 
                      
Figure: 14  
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Invitro Dissolution Studies of Domperidone Microparticles 
S.No
. 
Tim
e (h) 
Abs 
(nm) 
Con. 
µg/ml 
Conc. 
Mg/ml 
Conc.200 
ml 
Loss CLS CDR % 
CDR 
1 1 0.039 0.43 0.04 8.666667 0.00 0.00 8.67 14.52 
2 1 0.051 0.57 0.06 11.33333 0.04 0.05 11.38 19.07 
3 2 0.072 0.80 0.08 16 0.06 0.11 16.11 26.99 
4 4 0.089 0.99 0.10 19.77778 0.08 0.19 19.96 33.45 
5 8 0.111 1.23 0.12 24.66667 0.10 0.29 24.95 41.81 
6 12 0.131 1.42 0.14 28.4 0.12 0.41 28.81 49.63 
7 18 0.149 1.66 0.17 33.11111 0.14 0.55 33.66 56.40 
8 24 0.177 1.97 0.20 39.33333 0.17 0.72 40.05 67.11 
 
Table 22 
 
Figure: 15 
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Invitro Dissolution Studies of Domperidone Microparticles 
S.No
. 
Time 
(h) 
Abs 
(nm) 
Con. 
µg/ml 
Conc. 
Mg/ml 
Conc.200 
ml 
Loss CLS CDR % 
CDR 
1 1 0.031 0.34 0.03 6.888889 0.00 0.00 6.89 11.54 
2 1 0.058 0.64 0.06 12.88889 0.03 0.05 12.94 21.68 
3 2 0.076 0.84 0.08 16.88889 0.06 0.11 17.00 28.49 
4 4 0.091 1.01 0.10 20.22222 0.08 0.20 20.42 34.22 
5 8 0.118 1.31 0.13 26.22222 0.10 0.30 26.52 44.44 
6 12 0.129 1.42 0.14 28.4 0.13 0.43 28.83 49.63 
7 18 0.158 1.76 0.18 35.11111 0.14 0.57 35.68 59.79 
8 24 0.169 1.88 0.19 37.55556 0.18 0.75 38.30 64.18 
 
Table 23 
 
Figure: 16 
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Curve fitting analysis: 
In order to describe the kinetics of the release process of drug in all formulations, various 
equations were used, such as zero-order rate equation, which describe the system where release rate is 
independent of the concentration of the dissolved species. The first-order equation describes the release 
from the systems where dissolution rate is dependent on the concentration of the dissolving species. 
Higuchi square root equation describes the release from system where solid drug is dispersed in insoluble 
matrix, and the rate of drug release is related to the rate of diffusion. The Korsemeyer-peppas equation is 
used to analyze the release of pharmaceutical polymeric dosage forms, when the release mechanism is not 
well known or when more than one type of release phenomena could be involved. The data obtained from 
in vitro dissolution studies were fitted to zero-order (figure17-26), first-order (figure27-36), Higuchi 
(figure37-46) and Korsemeyer–Peppas (figure47-56) equations. 
The dissolution data obtained were plotted as Time versus cumulative percent drug released as 
zero order, Time versus log cumulative percent drug remaining as First order release kinetics, Square root 
of time versus cumulative percent drug released as Higuchi equation and Log time versus log cumulative 
percent drug released as per Korsemeyer-Peppas equation. 
Invitro Release Profile of Zero Order For Formulations F1 To F10 
 
Figure 17: Time vs. Cumulative % drug release for F1 formulation  
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Figure 18: Time vs. Cumulative % drug release for F2 formulation  
 
Figure 19: Time vs. Cumulative % drug release for F3 formulation  
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Figure 20: Time vs. Cumulative % drug release for F4 formulation  
 
 
Figure 21: Time vs. Cumulative % drug release for F5 formulation  
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Figure 22: Time vs. Cumulative % drug release for F6 formulation  
 
 
Figure 23: Time vs. Cumulative % drug release for F7 formulation  
 
y = 3.969x 
R² = 0.670 
0
20
40
60
80
100
120
0 5 10 15 20 25 30
%
C
D
R
 
Time(hrs) 
Zero order drug release kinetics-F6 
y = 4.129x 
R² = 0.653 
0
20
40
60
80
100
120
0 5 10 15 20 25 30
%
C
D
R
 
Time(hrs) 
Zero order drug release kinetics-F7 
     Page 90 of 118 
     
 
Figure 24: Time vs. Cumulative % drug release for F8 formulation  
 
 
Figure 25: Time vs. Cumulative % drug release for F9 formulation  
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Figure 26: Time vs. Cumulative % drug release for F10 formulation  
 
IN VITRO RELEASE PROFILE OF FIRST ORDER FOR FORMULATION F1 to F10 
 
                  Figure 27: Time vs Cumulative % drug retaining for F1 formulation  
 
y = 3.382x 
R² = 0.633 
0
10
20
30
40
50
60
70
80
90
0 5 10 15 20 25 30
%
C
D
R
 
Time(hrs) 
Zero order drug release kinetics-F10 
y = 0,0451x + 0,9429 
R² = 0,4785 
0
0,5
1
1,5
2
2,5
0 5 10 15 20 25 30
lo
g
 %
C
D
R
 
Time 
First order kinetics-F1 
     Page 92 of 118 
     
 
                 Figure 28: Time vs Cumulative % drug retaining for F2 formulation 
 
 
                  Figure 29: Time vs Cumulative % drug retaining for F3 formulation 
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                  Figure 30: Time vs Cumulative % drug retaining for F4 formulation 
 
 
                  Figure 31:Time vs Cumulative % drug retaining for F5 formulation 
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                 Figure 32: Time vs Cumulative % drug retaining for F6 formulation 
 
 
                  Figure 33: Time vs Cumulative % drug retaining for F7 formulation 
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                   Figure 34: Time vs Cumulative % drug retaining for F8 formulation 
 
 
                  Figure 35: Time vs Cumulative % drug retaining for F9 formulation 
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                 Figure 36: Time vs Cumulative % drug retaining for F10 formulation 
 
In vitro drug release profile of Higuchi model for formulation F1 to F10 
 
Figure 37: Square root of time vs cumulative % drug release for F1 formulation 
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Figure 38: Square root of time vs cumulative % drug release for F2 formulation 
 
 
 
Figure 39: Square root of time vs cumulative % drug release for F3 formulation 
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Figure 40: Square root of time vs cumulative % drug release for F4 formulation 
 
 
Figure 41: Square root of time vs cumulative % drug release for F5 formulation 
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Figure 42: Square root of time vs cumulative % drug release for F6 formulation 
 
 
Figure 43: Square root of time vs cumulative % drug release for F7 formulation 
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Figure 44: Square root of time vs cumulative % drug release for F8 formulation 
 
 
Figure 45: Square root of time vs cumulative % drug release for F9 formulation 
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Figure 46: Square root of time vs cumulative % drug release for F10 formulation 
 
In vitro release profile of Korsemeyer’s-Peppas model for Formulation F1 to F10 
 
Figure 47: Log time vs log cum % drug release for F1 Formulation 
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Figure 48: Log time vs log cum % drug release for F2 Formulation 
 
 
Figure 49: Log time vs log cum % drug release for F3  Formulation 
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Figure 50: Log time vs log cum % drug release for F4 Formulation 
 
 
Figure 51: Log time vs log cum % drug release for F5 Formulation 
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Figure 52: Log time vs log cum % drug release for F6 Formulation 
 
 
Figure 53: Log time vs log cum % drug release for F7 Formulation 
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Figure 54: Log time vs log cum % drug release for F8 Formulation 
 
 
Figure 55: Log time vs log cum % drug release for F9 Formulation 
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Figure 56: Log time vs log cum % drug release for F10 Formulation 
 
Formulation 
code 
Zero order 
R2 
First order 
R2 
Higuchi’s 
R2 
Korsemeyer’s 
 
N 
F1 0.639 0.478 0.983 0.732 
F2 0.642 0.388 0.935 0.659 
F3 0.681 0.343 0.902 0.619 
F4 0.611 0.410 0.973 0.672 
F5 0.640 0.466 0.981 0.730 
F6 0.670 0.404 0.959 0.673 
F7 0.653 0.408 0.961 0.608 
F8 0.693 0.434 0.976 0.698                                                                                                                        
F9 0.637 0.410 0.973 0.668 
F10 0.633 0.428 0.953 0.671                                            
                                                                   
    Table: 24  
 
y = 0,5421x 
R² = 0,6716 
0
0,5
1
1,5
0 0,5 1 1,5 2
lo
g
 %
 C
D
R
 
Log time 
Korsemeyer's drug release kinetics-
F10 
     Page 107 of 118 
     
           DISCUSSION 
Microparticles are solid, approximately spherical particles made up of polymeric substances, in 
which the drug is dispersed throughout the microparticles matrix. It contains an active agent or core 
material surrounded by a shell or coating of polymers. The shell is a continuous, porous or nonporous, 
polymeric layer. In biological systems, microparticles are small membrane bound vesicles circulating in 
the blood derived from cells that are in contact with the bloodstream such as platelets and endothelial cell. 
The bonds that link one polymer chain to another are covalent bonds or ionic bonds. Polymer 
chains are referring to synthetic polymers or natural polymers. Intermediate cross-link densities transform 
gummy polymers into materials that have elastomeric properties and potentially high strengths. Very high 
cross-link densities cause materials to become very rigid or glassy. The erosion of the polymer begins with 
the changes in the microstructure of the carrier as water penetrates within it leading to the plasticization of 
the matrix finally leads to the cleavage of the hydrolytic bonds.  
The cleavage of the bond is also facilitated by the presence of the enzyme in the surroundings. The erosion 
of the polymer may either surface or it may be bulk leading to the rapid release of water uptake therefore 
determines release profile of the system and depends on type of the polymer, porosity of the polymer 
matrix, protein drug loading. Microparticles provide the ability to manipulate the invitro action of the 
drug, pharmacokinetic profile, tissue distribution and cellular interactions of the drug. 
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PREFORMULATION PARAMETERS:   
Compatibility studies: 
The drug-excipient interaction study was carried out using FT-IR i.e. by KBr pellet method  
 
 Fourier Transform Infrared Spectroscopy:  
In the FT-IR drug-excipients interaction study, it was found that Domperidone was compatible 
with all the excipients used in the formulation. There were no extra peaks observed. Thus the chosen 
excipients for the formulation were found to be compatible with the active ingredient and have no physical 
interaction with the active pharmaceutical ingredient. 
Determination of λ max of Domperidone: 
On the basis of preliminary identification test it was concluded that the drug complied the preliminary 
identification. By scanning the drug in U.V spectrophotometer in 200-400 nm range, a sharp peak was 
observed at 284 nm using methanol as solvent. It was concluded that the drug has Ȝmax of 284nm. 
Preparation of standard calibration curve of Domperidone: 
From the standard curve of Domperidone it was observed that the drug obeys Beer’s law in the range 2-
20ȝg/ml and the equation was generated, Absorbance = 0.021 Concentration + 0.000, was used to 
calculate the drug content and % CDR of the dosage form. 
FORMULATION OF DOMPERIDONE MICROPARTICLES: 
Microparticles were prepared ionic-gelation method. Pectin, guar gum and xanthun gum were used as 
polymers to prepare Microparticles and methanol was used as a solvent. Morphology of Microparticles, 
%Entrapment efficiency, Drug content, Particle size and invitro drug release were selected as dependent 
variables. 
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EVALUATION PARAMETERS:  
Morphology of Microparticles: 
The shape of all formulations was found as smooth and spherical in shape. 
 Entrapment efficiency: 
Highest entrapment efficiency of 80.24 %was obtained with formulation F5. Lowest entrapment 
efficiency of 23.1% was obtained with formulation F1. For all other formulations (F2 to F10) the 
entrapment efficiency was found in between minimum and maximum values. 
Drug content: 
The highest drug content was found to be as 88.83% for F5 formulation and lowest as 40.0% for F1 
formulation. For all other formulations (F2 to F10) the drug content was found in between minimum and 
maximum values. 
In vitro drug release: 
In first hour of dissolution studies the drug release was observed ranging from 10.58% to 18.42 % for all 
the formulations. As the Microparticles show the 100% release for 24 hours all the formulations had 
shown only 76.26% to 54.09% maximum release for 12 hours. F7 formulation showed the sustained 
release than other formulations.  
Curve fitting analysis: 
In order to deduce the probable mechanism of drug release from the dosage form, the results of in vitro 
dssolution studies were fitted to various kinetic equations. When the data was subjected to zero order and 
first order kinetics model, a linear relationship was observed with high’ r2 ‘ values for zero order model as 
compared to first order model and it suggested that the formulations followed zero order controlled 
release. 
Higuchis model was applied to the invitro release data, linearity was obtained with high r2
 
values 
suggested that the drug release from the Microparticles followed dissolution mechanism. 
     Page 110 of 118 
     
      8.SUMMARY 
Domperidone is an anti-dopaminergic drug agent that is used orally, rectally or intravenously, in 
general to suppress nausea and vomiting, as a prokinetic agent and for promoting lactation. It is a specific 
blocker of dopamine receptors. It speeds gastrointestinal peristalsis, causes prolactin release, and is used 
as antiemetic and tool in the study of dopaminergic mechanisms. 
. 
In the research work an attempt was made to formulate and evaluate the domperidone 
Microparticles for sustained effect. The domperidone microparticles were prepared by using ionic-gelation 
method. 
The drug-excipients compatibility studies were carried out by using FT-IR technique. Based on the 
results, excipients were found to be compatible with Domperidone. 
In preformulation study, estimation of Domperidone was carried out by systronics UV 
spectrophotometer at Ȝ max 284 nm using methanol as solvent, which had a good reproducibility and this 
method was used in entire study. 
Formulations were prepared by using pectin, xanthun gum, guar gum as  polymers and methanol is 
used as a solvent. The Morphology of Microparticles, Drug content, %entrapment efficiency, invitro drug  
release was evaluated. 
Entrapment efficiency ranging from 54.04% to 76.26% was obtained. The shape of Microparticles 
of all formulation was found as smooth and spherical in shape. In 12 hours the drug release was observed 
ranging from 79.79% to 54.09%. 
        In order to deduce the probable mechanism of drug release from the dosage form, the results of in-
vitro dissolution studies were fitted to various kinetic equations.  
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        When the data was subjected to zero order and first order kinetics model, a linear relationship was 
observed with high’ r2 ‘ values for zero order model as compared to first order model and it suggested that 
the formulations followed zero order controlled release. 
Future scope: 
o In vivo studies can be done by using a suitable animal model 
o In vitro-in vivo correlation studies can be done. 
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9.CONCLUSION 
The present study was an attempt to optimize and characterize the Domperidone microparticles. 
The main interest in such a dosage form was made to formulate Domperidone for sustained effect and to 
increase bioavailability. 
Domperidone is an anti-dopaminergic drug agent that is used to suppress nausea and vomiting, as 
a prokinetic agent and for promoting lactation. It is a specific blocker of dopamine receptors, speeds 
gastrointestinal peristalsis, causes prolactin release. Domperidone microparticles were prepared by using 
natural polymers pectin, guar gum, Xanthun Gum by ionic-gelation method by using methanol as solvent. 
       
The drug and excipients compatibility was studied by FT-IR, which shows there is no chemical or 
physical interaction between drug and excipients. 
The results indicate that Domperidone microparticles could be successfully formulated by ionic-
gelation method to obtain maximum yield, entrapment efficiency, desired morphology, desired and drug 
release. 
The regression coefficient values for peppas model were found to be high, indicating adequate 
fitting. Among all the ten formulations, F5 possess the highest entrapment efficiency and F7 possess 
satisfactory Invitro drug release studies for extended period of time. So F5 and F7 were considered to be 
the best formulations. 
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11.ABBREVATIONS 
PMMA : poly methyl methacrylate 
DEAE  : diethylaminoethyl cellulose 
NHS  : N-hydroxysuccinimide 
BS3  : bissulfosuccinimidyl suberate 
EDC  : 1-Ethyl-3-(3-dimethylaminopropyl)carbodiimide 
SMCC  : succinimidyl-4(N-maleimidomethyl)cyclohexane-1 carboxylate 
PLGA  : poly Lactic-co-Glycolic Acid (PLGA) 
PLA  : polylactic acid 
PEO  : polyethylene oxide 
DMSO  : Dimethyl sulfoxide 
PBS  : phosphate Buffered Saline 
HPH  : high pressure homogenization 
AFM  : atomic force microscopy 
STM  : scanning tunneling microscopy 
AUC  : area under curve 
DDS  : drug delivery system 
PS  : particle size 
Gm  : gram 
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mL  : milli Liter 
 mg  :  milli gram 
mV  : milli volts 
nm  : nano meter 
 cm  : centimetre 
mm  : millimetre 
  hr  : hour 
  µg/ml  : micrograms per litre. 
